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1
MOTIVATION AND THESIS OUTLINE
1.1 Motivation
According to the World Health Organization, cardiovascular diseases (CVDs) are the first cause
of death worldwide. About 17.9 million people died from this cause in 2017, representing ap-
proximately a third of the global deaths [180]. CVDs are a cluster of disorders triggered by
multifactorial conditions in heart and blood vessels. CVDs encompasses stroke, rheumatic heart
diseases, cardiomyopathies or coronary artery disease (CAD, such as angina and myocardial in-
farction) among others. Particularly, CAD is the most important disease in terms of mortality,
causing more than 50% of the deaths [92, 102, 124, 180].
During the last decades, the cardiovascular community has put many efforts in the pre-
vention, diagnosis and treatment of CVDs [19, 41, 65, 92], with many guidelines and reports
frequently published and updated [164, 222]. One of the aims of these reports is to encourage
change in patient care from a population-wide intervention, in order to attenuate risk in patients
who have not yet established the disease. This is the so-called primary prevention, devoted to
prevent CVDs by promoting a healthy lifestyle throughout life [7]. The secondary prevention
of CVDs is about reducing the risk in patients with established disease. The guidelines at this
point are at an individual-level intervention [198], such as lipid management through treatment
with statin therapy, or blood pressure and weight control.
The cost-effectiveness of these primary and secondary interventions has been demonstrated
[8, 65, 67, 68, 123], and, although CVDs have been the leading cause of mortality in the world
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for more than two decades, with a vast majority of these cardiovascular deaths occurring in low-
and middle- income countries [102, 125, 180], a declining trend in the mortality by CAD has
been observed during the last years [148].
This trend cannot be solely attributed to the preventive guidelines [141], but also to the
advances in evidence-based medical (i.e. development of antithrombotic agents) and surgical
treatments (percutaneous coronary interventions) [63, 210]. The advances made in the last
decades have resulted in a reduction in morbidity and mortality of CVDs. As a consequence, the
higher survival rate after an acute event has raisedn the number of patients that suffer from a
chronic cardiovascular disease as a result of the underlying CAD. Nevertheless, left regional or
global ventricular dysfunction associated with CAD may not be irreversible; a substantial number
of patient will find a functional recovery of myocardium after coronary artery revascularization
[54, 103, 145].
In this line, the American College of Cardiology/American Heart Association (ACC/AHA)
task force has presented a set of guidelines for the initial clinical assessment of patients present-
ing heart failure [92]. There, they highly recommend the use of non-invasive imaging techniques
to evaluate the eligibility of revascularization [92] by assessing two important physiological pa-
rameters, the myocardial blood flow (MBF) and the myocardial viability. Several non-invasive
imaging techniques can perform these assessments, including: single photon emission computed
tomography (SPECT) [139, 215], cardiac magnetic resonance (CMR) [62], echocardiography
(EC) [120, 144], or positron emission tomography (PET) [43, 46, 135, 153, 189].
Among all these techniques, PET has been considered a “gold standard” for MBF and
viability assessment [15, 20, 50, 111, 217], thanks to its quantitative nature and superior detection
sensitivity [28].
However, despite its recognized high diagnostic value, the situation of cardiac PET in clin-
ical routine is far from optimal. Many factors impede its implementation worldwide, especially
the complexity and cost of scanners, and, more importantly, the complexity of production, short
physical half-life and low availability of PET radiotracers. Under these circumstances, we under-
stand that the development of novel translational perfusion PET radiotracers must be focalized
in their ease and low-cost production and high availability, without losing its diagnostic value.
1.2 Objectives
The goal of this thesis is to explore new applications of a 68Ga-labeled radiotracer (68Ga-DOTA∗)
in order to contribute to the expansion of cardiac PET in the clinical setting. We will focus in
this radiotracer because of its potential high affordability thanks to its generator-based obten-
tion. During this work we will study and validate the capability of this tracer to assess many
cardiovascular-related parameters such as MBF and viability, among others. Furthermore, we
will propose and study a new methodology that will permit the use of more than one radiotracer
∗DOTA is the abbreviated name of the chelator 1,4,7,10-tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid
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in a single scan. With this methodology, multiple-tracer scans could be performed, and in so
doing, the high cost usually attributed to PET scans could be dramatically reduced.
1.3 Thesis outline
In Chapter 2 we will introduce all the concepts that are necessary to understand the rest of the
thesis. This introduction is not intended to be neither an original nor an exhaustive compendium
of the topics related to cardiovascular PET and its clinical applications, but rather a mere
summary of well-known concepts that are thoroughly described in many articles, reviews and
books. On the other hand, the rest of the thesis is the result of the original multidisciplinary
work that has been carried out for the last four years by the author with the invaluable help of
his collaborators and supervisors. This work is structured as follows:
In Chapter 3 we will present 68Ga-DOTA as a PET radiotracer able to provide in vivo
assessment of myocardial blood flow. The measurements obtained will be compared against
those simultaneously obtained with fluorescent microspheres, which are considered to be the
gold standard for perfusion measurements. The studies were carried out in pigs under rest and
stress conditions.
In Chapter 4 we will evaluate the capability of this same radiotracer to assess another
important physiopathological parameter, the extracellular volume fraction of the myocardial
tissue, which provides an idea of myocardial viability. In this case, the proof of concept was
tested in a swine model of myocardial infarction.
In Chapter 5, we will focus in pulmonary perfusion. In this part, we will validate 68Ga-
DOTA as a pulmonary blood flow PET-tracer in healthy pigs. Once more, the results were be
validated against those obtained by fluorescent microspheres as gold-standard measurements.
For the rest of the thesis we will move from single tracer scans to multiple-tracer scans.
In Chapter 6 we will propose a new methodology that will permit us to perform dynamic
PET scans with more than one radiotracer simultaneously. For that purpose, we combined 68Ga-
DOTA with 18FDG. This new methodology, which is based on the spectroscopic analysis of blood
samples manually obtained from the subject, will be proposed and validated both in vitro and
in vivo.
In Chapter 7 we will present a blood sampling detector that will be able to perform the
methodology introduced in the previous chapter in an automated fashion, so that human inter-
vention will be minimized and, with that, radiation exposure of the technical personnel. The
detector will be presented and characterized, and its performance evaluation in vitro and in vivo
will be shown.
To conclude, in Chapter 8 we will present the final remarks of this work.
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2
INTRODUCTION
2.1 Principles of PET
Positron Emission Tomography (PET) is a non-invasive imaging technique that allows in vivo
monitoring of metabolic processes in an organism. It is based on the detection of the gamma
rays resulting from the annihilation of the positrons emitted by a radiotracer that has been
administered to the subject. These radiotracers are chemical compounds in which one or more
atoms have been replaced by a radionuclide that emits a positron following a β+ decay. In this
process, two annihilation photons are emitted (almost) collinearly in opposite directions. The
PET camera is formed by several rings of detector blocks in which these annihilation photons
may incide and produce an electric pulse. All these pulses are collected and processed and,
finally, an image of the radioactivity distribution inside the subject is obtained.
2.1.1 β+ decay
As explained above, the radiotracers utilized in PET are labeled with β+-emitter radionuclides.
A β+ decay process can be described as:
p→ n + e+ + νe . (2.1)
In this process, the proton (p) is converted into a neutron (n), a positron (e+) and an electron
neutrino (νe). However, this β+ decay process cannot occur in isolated protons, due to energy
constrains [165]. It can only occur in proton-rich atoms, that achieve stability by converting a
5
6 Chapter 2: Introduction
proton into a neutron:
A
ZX→ AZ−1Y + e+ + νe . (2.2)
The emitted positron has an initial energy that can take a continuum of values up to a maximum
[16]. This maximum energy differs among radioisotopes, being an intrinsic parameter of the
radionuclide. There are many other properties (such as half-life of the parent nucleus, way of
production or branching ratio) that differ between radioisotopes. This has contributed to propose
many as labeling agents since the development of the first PET scanners more than forty years
ago [162, 207]. Please refer to section 2.1.6 for more information on these properties.
2.1.2 Interaction of radiation with matter
Since its emission from the β+ decay, the positron travels a finite distance (usually a few mil-
limeters) while losing kinetic energy by interactions with the surrounding matter (via ionization
events with other atoms or by radiation after an inelastic scattering) [110]. Once it has lost all
of its kinetic energy, the positron annihilates with an electron nearby (in fact, they momentarily
form an onium, an exotic atom composed by the electron and the positron orbiting around their
center of mass) and produces two annihilation gamma rays. These gamma rays have an energy
of 511 keV each, and they are emitted in (almost) opposite directions to conserve momentum.
Gamma rays interact with matter by three main types of interactions: photoelectric absorp-
tion, Compton scattering and pair production. However, pair production is only energetically
possible when the gamma ray energy exceeds the sum of the electron and positron masses (1.022
MeV) and hence, it is not possible from an annihilation photon. Consequently, the high-energy
photons emitted by the e+e− annihilation interact with surrounding matter mostly by photoelec-
tric absorption and Compton scattering, which are further briefly described:
– In the photoelectric absorption an atom absorbs totally the energy of the incident photon.
As a result, this photon disappears and the absorbed energy is employed to eject an orbital
electron (called photoelectron) from the absorber atom. This photoelectron has a kinetic
energy given by:
Ee− = hν − Eb , (2.3)
where Eb is the binding energy of the photoelectron to the atom’s shell where it comes
from.
– Compton scattering is a collision between a photon and a loosely bound orbital electron
(termed as recoil electron) [35]. In this kind of interactions, the incoming gamma ray
deflects through a certain scattering angle θ and transfers part of its energy to the recoil
electron. Compton scattering is the predominant interaction mechanism for annihilation
photons. The energy of the scattered photon (Eγ′) is related to its scattering angle (θ) by
the following expression:
Eγ′ =
Eγ
1 + (Eγ/mec2)(1 − cosθ) , (2.4)
where me is the electron rest mass (511 keV) and Eγ is the energy of the incident photon.
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The probability that an annihilation gamma ray experiences an interaction when passing through
a certain thickness of a material, essentially depends on its energy and the composition and
the thickness itself, and it is denoted as the attenuation coefficient µ. Since PET is based on
the detection of annihilation photons that have not interacted within the subject, an extended
description of PET detectors is given below.
2.1.3 PET detection systems
The objective of PET detectors is to convert the incident radiation emitted from the radioactive
source into a measurable electric signal that can be quantified and digitized. Radiation detectors
can be generally divided into three broad categories [9, 110]: proportional (gas) chambers, semi-
conductor detectors and scintillation detectors. Scintillation detectors are the most commonly
used in PET detection systems and hence they are presented here with more detail.
Scintillation detectors are detection systems composed by a scintillator (a special material
able to convert part of the energy released after the radiation absorption into visible light)
coupled to a photodetector (a light detection system that converts the visible light into electrical
current). There are many properties that determine the performance of a scintillator. Table 2.1
shows some of the most commonly used scintillators in PET devices along with their properties
[116].
Table 2.1: Physical properties of common scintillators for PET.a
Scintillator NaI BGO GSO LSO LYSO LGSO LuAP YAP LaBR3
Peak emission wavelength (nm) 410 480 430 420 420 415 365 350 360
Index of refraction 1.85 2.15 1.85 1.82 1.81 1.80 1.94 1.95 1.90
Light output (103 ph/MeV) 41 9 8 30 30 16 12 17 60
Decay time (ns) 230 300 60 40 40 65 18 30 16
Density (g/cm3) 3.67 7.13 6.71 7.35 7.19 6.5 8.34 5.5 5.3
Effective Z 50 73 58 65 64 59 65 33 46
Hygroscopic Yes No No No No No No No Yes
Magnetic susceptibility No No Yes No No Yes No No No
a Table modified from [116].
The light outputted by the scintillator material is converted into an electrical current by a
photodetector. Most clinical PET scanners use photomultipliers (PMTs) as photodetectors, due
to its unique combination of very high gain (> 106), low noise and fast response relative to other
photo-sensing devices [116]. Avalanche photodiodes (APDs) are another kind of photodetectors.
They are semiconductor devices insensitive to magnetic fields and with a larger photon detection
ratio compared to PMTs. However, APDs are not frequently utilized in PET due the fast front-
end electronics required for processing signals coming from individual APDs [218].
A viable alternative to PMTs are silicon photomultipliers (SiPMs) [174]. These are single-
photon-sensitive devices [173] based on single-photon APDs densely packed on a silicon substrate.
SiPMs possess extremely high sensitivity, high gain and low operating voltage. SiPMs can also
work under the presence of a high magnetic field, which makes them a perfect substitute of
PMTs [53, 112, 225] in bimodal positron emission tomography/magnetic resonance (PET/MR)
scanners that have received increasing attention in recent years [152, 208].
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All the electric pulses produced by the photodetectors are continuously digitized and as-
sociated to unique time-energy-position events. These recorded events are associated to pairs
of coincidences and further analyzed to produce the final image. Data reconstruction and the
subsequent corrections applied to the final image are detailed below.
2.1.4 Reconstruction algorithms
One of the advantages of PET against other tomographic imaging techniques is that PET is
based on detection of the two gamma rays emitted from each e+e− annihilation. In order to
obtain a final image of the radiotracer distribution inside the administered patient, all the events
recorded during the acquisition need to be appropriately processed. However, it is out of the
scope of this introduction to detail the different reconstruction algorithms available. There are
two main categories of reconstruction algorithms: analytical and numerical (iterative).
The most common analytical reconstruction algorithm is the filtered backprojection (FBP).
This algorithm essentially performs the Fourier transformation of angular projections, applies
the ramp filter in the frequency domain, performs the inverse-transform of the resultant product,
backprojects the filtered projection and sums over all filtered projections [205, 209].
The iterative reconstruction algorithms are based on the attempt to maximize or minimize a
target function determined by the particular algorithm used [205]. They usually provide a more
accurate estimate than analytical methods, at expense of more computational demand. One
of the most widely used iterative algorithms is the ordered subsets expectation maximization
algorithm (OSEM) [45], which is an accelerated version of the maximum-likelihood expectation
maximization (ML-EM) method. The last iterative method worth to be mentioned is the 3D-
dedicated row-action maximum-likelihood algorithm (3D-RAMLA) [32], which is a (theoretically
faster) special case of OSEM and it is implemented on many clinical PET scanners.
2.1.5 Data corrections
The reputation of PET as a quantitative imaging tool is largely based on the fact that an exact
correction for attenuation of the signal is theoretically achievable. However, this and many other
factors (such as count-rate losses, variations in detector efficiency, detection of scattered events,
etc) have an impact on the quantitative accuracy of resultant PET images. In this section, these
sources of error are described along with the approaches used to correct them.
Decay
In some PET studies, data are acquired over time periods similar to the half-life of the admin-
istered radionuclide [35]. In such situations, a correction by the physical decay occurred during
the measurement time interval must be carried out. The decay-corrected activity during the
time frame in which PET acquisition has been conducted is given by:
D =
(t2 − t1)λe−λt1
1 − e−λ(t2−t1) , (2.5)
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where λ is the decay constant of the employed radionuclide, and t1 and t2 are the start and end
times of the PET frame. Whenever λ and the timeframe start and duration are known, decay
correction will be possible.
Scatter
As previously stated, annihilation photons emitted from the β+ decay may interact with sur-
rounding matter and scatter. As a consequence, the gamma ray will deflect and lose part of its
energy. Many of these scattered photons never reach a detector, but there is a percentage that
may still hit one of the detectors, provoking a so-called scatter coincidence. Such scatter events
can be discriminated from true events on the basis of their energy. However, this approach is
not optimal, because photons are more likely to scatter at small angles, thus losing less energy.
Therefore, a very good energy resolution is needed to discriminate them from the true 511 keV
ones. To overcome this situation, apart from improving energy resolution, most clinical scanners
have already implemented sophisticated algorithms [119, 226].
Attenuation
The probability of interaction of a photon with a certain energy with matter is given by the
attenuation coefficient µ, which depends on the energy itself, along with the electron density of
the material. However, due to the fact that PET is based on the detection of coincident photons,
the attenuation probability of a coincidence event does not depend on the location within the
line that virtually joins the two opposite detectors (known as line of response, LOR) but on the
thickness of material that both photons (in sum) have to cross [14] and the material itself. In the
past, the most common attenuation correction method involved the performance of a transmission
scan (a scan of the patient before radiotracer injection with radioactivity emitted by an external
rotating radioactive source) and a blank scan (a scan without the patient). The difference in the
counts detected between both scans was assumed to be only caused by attenuation through the
patient. Another possibility is the CT-based correction method, in which attenuation coefficient
for every voxel within the field of view (FOV) is derived from CT Hounsfield units, and then a
correction is applied to the final image. Due to the popularity and success of combined Positron
Emission Tomography/Computed Tomography (PET/CT) scanners, this is the most common
attenuation correction approach.
Random coincidences
It is possible for two photons that did not come from the same annihilation to be erroneously
identified as having occurred simultaneously (actually, they are not simultaneously detected but
are measured within the resolving coincidence time window τ in which the scanner works). In
this case, the scanner unavoidably treats this detection as an annihilation produced somewhere
in the line between the two detectors where the (not truly related) gamma rays entered [49]. Such
false coincidence is called a random coincidence. Random coincidences produce a background
noise over the resultant image, and its magnitude depends on the radioisotope distribution. The
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number of random coincidences per second (Ri j) proportionally depends on τ:
Ri j = 2τrirj , (2.6)
where τ is the coincidence resolving time of the scanner, and ri and rj are the counts per second
(singles rate (SR)) of two independent detectors. Two main approaches may correct for this
undesired effect. In the first one, Ri j can be determined for every pair of detectors by estimating
each SR [49]. The second approach utilizes a delayed coincidence channel, in which timing signals
from one detector are delayed by a time much greater than τ [110]. In this way, any coincidence
measured by the delayed channel can only be random. Once the random coincidence rate is
known, it can be subtracted from the measured true events.
Partial volume effect (PVE)
Partial volume refers to the apparent loss of activity concentration within a certain region of
interest (ROI) of the PET image. Due to limitations in spatial resolution and tissue sampling, the
true activity concentration does not correspond with the activity concentration that is actually
measured. This apparent loss of activity is figuratively said to spilled in (or spilled out ) of the
ROI, so that the measured activity concentration is lower (or greater) than what it should be,
ideally. PVE can severely affect PET images both qualitatively and quantitatively. Hence, a
partial volume correction (PVC) is usually applied. There are many PVCs that can be applied
[199]. Recovery coefficient [202] (in which a correction factor that accounts for the estimated
count loss is applied to the ROI) is a simple method commonly used in PET tumor imaging [71,
88]. A more complex method is the geometric transfer matrix method [181], which can account
for spillover among any number of structures.
2.1.6 PET radionuclides
Since the development of the first PET scanner [162, 207] many radioisotopes have been pro-
posed as labeling agents according to different physical properties and production pathway (see
Table 2.2). The most important properties that can determine the use and success of a PET
radioisotope are [37]:
Half-life
The half-life is defined as the time required for half of the original population of the radionuclides
to decay. Usually half-lives of the radioisotopes used in PET are short (in the order of seconds
to minutes). This is advantageous in terms of radiation safety, as it translates into a reduced
radiation dose delivered to patients and clinical personnel. However, with a short half-life time,
production and managing of radiotracers are limited to specific and costly facilities, thus limiting
its implementation on clinical use.
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Positron range
The maximum kinetic energy of the emitted positron is directly proportional to its range in the
tissue. As a consequence, PET images obtained from short-range positron emitters (such as 11C,
18F or 89Zr) will have better spatial resolution than those obtained from long-range ones. The
lower the positron range, the less blurred final PET image.
Prompt gamma emission
Some of the positron-emitter radioisotopes obey to a decay scheme in which they also emit
additional prompt gamma rays [37, 131]. This property could lead to PET image blurring due
to the production of multiple coincidences. However, this additional gamma ray emission may
become beneficial in some situations such as in multiple-tracer scans, as we will see in Chapters
6 and 7.
Branching ratio
Radionuclides may have more than one decay mode, and the branching ratio defines the prob-
ability that a certain decay mode takes place. β+ decay may compete with electron capture,
another decay mode in which an orbital electron is captured by the nucleus and combines with a
proton to form a neutron. As an example, 88.9% of the decays of 68Ga into 68Zn are by positron
emission (almost 99% of these decays produce a positron with a maximum energy of 1.899 MeV
and 1% produce a positron with a maximum energy of 822 keV), and 11.1% are by electron
capture. In this case, the β+ decay branching ratio for 68Ga would be 0.889 as seen in Table 2.2.
Branching ratio not only applies to β+ decay mode but to all kind of decays. Table 2.2 also
reflects prompt-gamma branching ratio, a parameter that will become of great importance in
Chapters 6 and 7. 68Ga results to be a non-pure positron emitter, i.e., sometimes 68Ga decays
into an excited state of 68Zn which promptly decays into a stable state of 68Zn through the
emission of an additional gamma ray. The energy of this gamma emission may take different
values, but the probability of those emissions (branching ratio) are all negligible except for the
one with Eγ = 1.077 MeV. This prompt gamma emission occurs 3.2 times per 100 decays of 68Ga.
Hence, Brγ(Ga) is considered to be 3.2%. Fig. 2.1 shows a simplified decay scheme of 68Ga.
Figure 2.1: Decay scheme of 68Ga.
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Production type
The vast majority of radioisotopes used in PET are produced from cyclotrons. Besides, some
of these radioisotopes (such as 11C, 13N, 15O or 18F) are elements present in most of biologic
substances, and therefore they can be used to label many biological molecules in order to monitor
processes that occur inside an organism. However, isotope production from cyclotrons is very
expensive due to the high cost derived from installation, maintenance and daily operation. This
is an important factor that limits the widespread use of PET worldwide.
Radionuclide benchtop generators are an alternative to cyclotrons. These devices contain
a mixture of the parent (the long-lived radionuclide that will undergo the β+ decay) and the
daughter (the short-lived radionuclide that results from the β+ decay). The parent is contin-
uously decaying into the daughter, so that the daughter can be continually obtained on site.
Consequently, radioisotopes such as 68Ga or 82Rb can be readily available in hospitals from
generators, which provides an almost unlimited daily production, avoiding costly cyclotrons.
Table 2.2: Most common radionuclides used in PET.a
Radionuclide Half-life
Emax(β+)
(MeV)b
Rmax
(mm)c
Brβ+
(%)d
Prompt γ
emitter
Emax(γ)
(MeV) Brγ(%) Production type
11C 20.3 min 0.96 4.2 99.8 No – – Cyclotron
13N 10.0 min 1.198 5.5 99.8 No – – Cyclotron
15O 2.0 min 1.732 8.4 99.9 No – – Cyclotron
18F 109.8 min 0.634 2.4 96.9 No – – Cyclotron
64Cu 12.7 h 0.653 2.5 17.5 No – – Cyclotron
68Ga 67.8 min 1.899 9.2 88.9 Yes 1.077 3.2 68Ge/68Ga Generator
76Br 16.2 h 3.382 17.1 32.1 Yes 0.559 , 0.657 74.0 , 15.9 Cyclotron
82Rb 1.3 min 3.378 17.0 94.9 Yes 0.777 15.1 82Sr/82Rb Generator
86Y 14.7 h 1.221 5.6 17.5 Yes 1.077 , 0.627 82.5 , 32.6 Cyclotron
89Zr 78.4 h 0.902 3.8 22.7 No – – Cyclotron
124I 100.8 h 1.535 10.0 22.4 Yes 0.602 , 1.691 62.9 , 11.2 Cyclotron
a Adapted from [16, 37].
b Energy of the most frequent β+ decay mode.
c Maximum range in water.
d Sum of Brβ+ of the two most frequent β+ decay modes.
2.2 The cardiovascular system
Now that we have introduced the basics of PET, and since this dissertation is focused on the
applications of PET for cardiovascular imaging, it is time to introduce some concepts related to
the human cardiovascular system.
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2.2.1 The heart and the coronary circulation
The cardiovascular system of humans is a closed network consisting of the heart, the blood and
the blood vessels, including arteries, veins and capillaries [132]. This system is intended to supply
tissues in the body with oxygen and other nutrients, transport hormones and remove metabolic
waste products (through the lymphatic system) [79]. The cardiovascular system actually has two
components, the systemic circulation and the pulmonary circulation. The pulmonary circulation
is in charge of blood oxygenation, whereas the systemic circulation is intended to deliver that
oxygenated blood to the rest of the body.
The heart is the main organ in the cardiovascular system. It is a hollow, muscular pump,
which main function is to propel blood throughout the body and plays a key role in both pul-
monary and systemic circulations. The heart has four chambers: right atrium, left atrium, right
ventricle, and left ventricle [203]. The atria are the two upper chambers, while the ventricles are
the two lower ones (see Fig. 2.2).
Figure 2.2: Diagram of the human heart. Blood flows following the direction of white arrows. (Illustration
“Diagram of the human heart (cropped)”, by wapcaplet, licensed under CC-BY 3.0).
Deoxygenated blood arrives to the right atrium from (mainly) the vena cava and the coronary
sinus. This blood is sent down to the right ventricle to be pumped through the pulmonary artery
to the lungs for re-oxygenation (see Fig. 2.3). After completing the pulmonary circulation loop,
it enters into the heart again, this time through the left atrium, which pumps the oxygenated
blood through the mitral valve into the left ventricle. The left ventricle is much thicker as
compared with the right, due to the greater force needed to pump blood to the rest of the body
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through the aortic valve to the aorta.
Figure 2.3: Pulmonary circulation in the heart. Deoxygenated blood flows following the blue arrows. After
oxygen exchange in pulmonary capillaries, it returns to the heart through the pulmonary veins as oxygenated
blood. Illustration (“2119 Pulmonary Circuit”, by OpenStax College, licensed under CC-BY 3.0).
Like the rest of the organs in the body, the heart muscle also needs a continuous supply of
oxygenated blood, and this is provided by the coronary arteries. This blood supply to the my-
ocardium is the so-called coronary circulation. Right above the aortic valve, there are two small
openings that permits a portion of that blood deviating to the heart muscle (the myocardium)
[25]. These two openings existing above the aortic valve, at the beginning of the aorta (the aortic
root) originate the two coronary arteries; the left coronary artery and the right coronary artery.
The left coronary artery bifurcates in two branches: the left anterior descending (LAD), and
the left circumflex (LCX) (see Fig. 2.4). These branches, along with the right coronary artery
(RCA) are the three main coronary arteries that supply blood to the heart muscle.
Figure 2.4: Anterior and posterior views of the coronary circulation in myocardium. The main coronary arteries
are highlighted in red. Illustrations licensed under CC-BY 3.0 [220].
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The coronary circulation is of major importance not only to the heart muscle, but also
to the rest of the body, including the brain. The heart is continuously pumping blood to the
rest of the body, and to do so it needs to be constantly supplied by oxygenated blood. The
slightest interruption in this supply may quickly provoke a heart attack, a situation in which
the myocardium results damaged by oxygen starvation. This and other diseases that affect
the cardiovascular system, and the coronary circulation in particular, are detailed in the next
subsection.
2.2.2 Cardiovascular disease
The cardiovascular disease (CVD) is the class of diseases that involve the heart and the blood ves-
sels. Many diseases are englobed under this classification; angina, myocardial infarction, stroke,
heart failure, pulmonary heart disease and pulmonary hypertension are only a few of them [221].
The major cause of CVD is atherosclerosis. Atherosclerosis is a chronic inflammatory condition in
which the inside of an artery narrows due to the formation of an abnormal accumulation of fatty
lipids, calcium, inflammatory cells and connective tissue, the so-called “plaque”. This plaque may
be formed in any artery in the body, including coronary arteries, and may stay asymptomatic
for a long period of time. However, when a coronary artery suffers a marked narrowing due to
the growth of the plaque, the blood flow supplied to the myocardium gets restricted and can
produce symptoms such as chest pain or angina pectoris. Moreover, if the blood flow to any part
of the myocardium is completely restricted for a few minutes, the consequent oxygen starvation
causes the myocardial cells of the affected zone to die or become damaged. This is known as
a heart attack, or myocardial infarction (MI). Angina or myocardial infarction are some of the
many diseases englobed under the term Coronary Artery Disease (CAD), also known as Ischemic
Heart Disease (IHD). CAD is the most common CVD [180], the leading cause of death, and is
predicted to remain so for the next years [133]. Hence, early and accurate diagnostic testing has
become a critical factor in the detection and optimal management of CAD. In the next section,
the possibilities of PET as a noninvasive diagnostic tool for CAD diagnosis are explored.
2.3 PET in cardiovascular disease
PET, and more recently combined PET/CT have been used for decades as a diagnostic and
prognostic tool for cardiovascular disease. Cardiac PET presents a wide variety of research ap-
plications; imaging myocardial innervation or fatty acid uptake, gene expression and gene therapy
monitoring, lesion detection in atherosclerosis, or hypoxia measurement, are some representative
examples [20, 130]. However, there are two main clinical applications of cardiac PET that stand
out over the rest: quantitative assessment of myocardial blood flow and assessment of myocardial
viability.
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2.3.1 Myocardial blood flow
The presence of high-grade coronary stenoses is a sign of obstructive CAD, and it can be detected
non-invasively by PET, but also by anatomical imaging techniques such as computed tomography
angiography. Nevertheless, the central goal nowadays has shifted from diagnosing obstructive
CAD to detecting patients who are at risk for developing CAD or who already have preclinical
(although not obstructive) CAD. This early diagnosis of patients at risk may translate into the
ability to prevent, halt progression of promote regression of atherosclerosis before it becomes
clinically overt [46].
PET is able to identify this subclinical CAD [189, 190] by assessing coronary microvascular
function. It can be identified by quantifying the hyperemic MBF (which represents the maximum
MBF achievable by the heart during maximum vasodilatation of the coronary vascular bed) and
comparing it against resting values. For that, rest/stress studies are performed and the ratio of
MBFs under stress and rest condition is calculated (stress may be induced by physical exercise
during the test or, whenever this is not possible, by pharmacological induction, typically through
adenosine). This ratio is called coronary flow reserve (CFR) and serves as an empirical cut-off to
decide whether there is an elevated cardiac risk (CFR under 1.5) or a favorable prognosis (CFR
over 2.3)∗ [227].
2.3.2 Radiotracers used for MBF assessment
Only a few radiotracers are clinically used for cardiac MBF assessment: 15O-labeled water
(H215O) [6, 22], 13N-labeled ammonia (13NH3) [93, 188] and 82Rb [87]. Additionally, a novel
18F-labeled radiotracer (18F-BMS-747158-02, known as 18F-Flurpiridaz) has been proposed and
validated in pigs [155] and humans [24, 127, 129] and it is currently in a phase III trial for clinical
use. Some characteristics of these radiotracers can be found in Table 2.3.
Table 2.3: Most common radiotracers used in cardiac PET for MBF assessment.a
Image resolution Myocardialextraction fraction
Pharmacological stress
imaging protocol
Treadmill exercise
imaging protocol
H215O Intermediate 100% Feasible Not feasible
13NH3 Intermediate-high 80% Feasible Feasible but not practical
82Rb Lowest 65% Feasible Not feasible
18F-Flurpiridaz Highest 94% Feasible Feasible
a Adapted from [128].
From the FDA-approved† radiotracers, H215O seems to be the ideal one, since it is a freely
diffusible tracer (i.e. its myocardial extraction fraction is the highest possible), and it does not
depend on the metabolic state of the myocardium [197]. However, H215O quickly reaches ac-
tivity concentration equilibrium between blood pool and myocardium, which may interfere in
the quantification, and therefore the blood pool contribution may be eliminated. Such elimina-
tion can be accomplished by acquiring a second set of images after a inhalation of 15O-labeled
∗These values are approximate; to date, there is no consensus over the optimal cut off values, and many
possibilities can be found in the literature.
†FDA refers to Food and Drug Administration: the federal agency of the US Department of Health and
Human Services that regulates the use of radiopharmaceuticals in humans.
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carbon monoxide (15CO), that irreversibly binds to hemoglobin in blood [52] and provides an
independent image of the blood pool, that will be subtracted from the main image. However,
this needed but impractical procedure is a limiting factor for the widespread implementation of
H215O in the clinical setting.
Regarding the promising 18F-Flurpiridaz, it also possesses some characteristics that may
convert it into a widely used MBF radiotracer in the future, if approved by FDA. Apart from
its high extraction fraction, it is a 18F-labeled drug, which facilitates a broader access to this
agent due to higher availability than on-site 15O and 13N cyclotrons and more adequate half-life
than 82Rb. Furthermore, its long half-life permits routine exercise stress testing, which is not a
feasible option for H215O or 82Rb. Apart from their physical and logistical characteristics, each
radiotracer provides a quantitative assessment of MBF by the analysis of dynamic PET scans.
However, this analysis may differ amongst radiotracers depending on their uptake mechanism,
and hence, each radiotracer may obey a different pharmacokinetic model. A more detailed
description of the two most relevant pharmacokinetic models used in this work can be found in
section 2.4.
2.3.3 Myocardial viability
After a prolonged reduction in blood flow provoked by a coronary artery obstruction, the my-
ocytes existing in the affected myocardial region commence to die due to the decreased oxygen
supply. Over the following weeks, the ischemic region follows a complex process [52] that ends
with the formation of a collagenous scar that lacks the structure necessary for the normal con-
traction. As stated above, the consequent loss of contractility may not be irreversible, though.
Predicting, to some extent, an eventual recovery after revascularization is the goal of myocardial
viability assessment. In order to get a full insight of the utility of myocardial viability, some
definitions must be presented:
– Scarred myocardium refers to the situation in which the loss of contractility is irreversible
due to high amount of fibrotic tissue replacing the myocytes that existed before the is-
chemia.
– Hibernating myocardium can be described as the chronic LV dysfunction due to reduced
MBF that can be partially or completely reversed after revascularization [168–170].
– Stunned myocardium refers to the acute post-ischemic dysfunction characterized by normal
flow but reduced function in the absence of myocardial necrosis [98], with gradual return
of contractile activity.
In the last two situations, myocardium is dysfunctional, albeit viable, i.e., it may return to its
normal function after revascularization. The ability to assess whether a myocardium is still viable
(either hibernating or stunned) or not (scarred) is of extreme importance in the management of
a patient that suffers from CAD or left ventricular dysfunction, as it may determine whether the
patient is suitable for revascularization [103].
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PET is accepted as the gold standard for viability assessment. A distinction between viable
and non-viable myocardium can be done by the combination of regional myocardial perfusion
(MBF) and myocardial metabolic activity measurement, as shown in Table 2.4. The regional
metabolic activity measurement is assessed by 18FDG [163, 171]. 18FDG refers to fluorodeoxyglu-
cose, a glucose analogue labeled with 18F. This molecule competes with glucose for uptake by
high-glucose-demanding cells such as cardiomyocytes. However, this molecule gets trapped inside
the cells after phosphorylation, as it lacks a 2-hydroxyl group present in normal glucose. Thanks
to this mechanism, it has been demonstrated that 18FDG uptake is directly proportional to the
utilization of exogenous glucose [171], making 18FDG a perfect radiotracer for metabolic activity
assessment.
Table 2.4: Characteristics of the different myocardial states.
Classification Perfusion Contractile function FDG uptake Metabolism
Nonischemic Normal Normal Normal Normal
Stunned Normal Reduced but reversiblea High Normal/increased
Hibernated Reduced Reduced but reversibleb High Normal/increasedc
Scarred Reduced/absent Reduced Low Reduced/absent
a Reversible in hours to weeks.
b Reversible in weeks to months.
c Perfusion-metabolism mismatch.
As a final remark, it must be pointed out that there is another interesting way to assess
the myocardial viability without monitoring the glucose uptake with 18FDG. It can be done
by analyzing the composition of the tissue remaining in the post-ischemic [160] regions. This
is routinely done by CMR, which can identify scarred and fibrotic tissue [109] by assessing
the extracellular volume fraction (ECV). ECV is described as the fraction of tissue that is not
occupied by cells. In this line, PET has been recently used to assess myocardial viability by
means of ECV quantification [108].
2.4 Pharmacokinetic modeling in cardiac PET
2.4.1 Compartmental models
PET imaging gives quantitative information about the biodistribution and kinetics of a ra-
diopharmaceutical throughout a target structure and/or organ. A single static image may be
collected at a specific time, but sometimes it may become more useful to record the time-course
biodistribution of the radiotracer by performing a dynamic PET scan. In such case, the time
dependence of the radiotracer biodistribution may give a deeper insight of the tracer kinetics,
and physiological parameters, such as blood flow or tracer binding, may be obtained.
The radioactivity concentration in a given tissue depends primarily on two factors; the
local physiology and the time-course of the tracer radioactivity concentration in blood or plasma
[16]. The relationship between the concentration and those two factors can be mathematically
modeled. Compartmental modeling is the most commonly applied method to determine the
uptake and clearance of radiotracers in tissue [4, 101]. In these models, each compartment refers
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to a possible state of the radiotracer, either physical (i.e., its location) or chemical (i.e., its binding
state) and a set of equations describe mathematically the movements between compartments.
The nature and number of these equations will depend on the number of compartments needed
to describe the behavior of the radiotracer imaged. The two most used pharmacokinetic models
employed in cardiac PET imaging are briefly described below.
2.4.2 One-tissue compartment model
The one-tissue compartment model (1TCM) describes the bidirectional flux of radiotracer be-
tween blood capillaries and myocardial tissue. The unidirectional radiotracer flux from blood to
tissue is given by K1Ca(t), and the unidirectional radiotracer flux from tissue to blood is given
by k2Ct (t). Therefore, the differential equation describing the rate of change of the radiotracer
tissue concentration is:
dCt (t)
dt
= K1Ca(t) − k2Ct (t) , (2.7)
where K1 describes the rate of entry of radiotracer from blood to tissue and has units of milliliter
of blood per minute per milliliter of tissue. k2 describes the rate of return of tracer from tissue
to blood, in units of fraction of radiotracer leaving the tissue per minute. The radiotracer
tissue concentration Ct (t) can be directly measured from PET images. Finally, the radiotracer
concentration in blood, Ca(t) (usually known as the Arterial Input Function, AIF) has to be
determined. It is usually measured either from the dynamic PET image, or from the analysis of
blood samples withdrawn from the scanned patient. Eq. 2.7 can be analytically solved, yielding
the following solution:
Ct (t) = Ca(t) ⊗ K1e−k2t , (2.8)
where ⊗ stands for the one-dimensional convolution.
2.4.3 Two-tissue compartment model
In the two-tissue compartment model (2TCM), the first tissue compartment refers to the ex-
travascular extracellular part of the tissue (the interstitial space), while the second compartment
refers to the intracellular space. The two differential equations that describe the radiotracer
concentration are:
dC1(t)
dt
= K1Ca(t) − (k2 + k3)C1(t) + k4C2(t) (2.9)
dC2(t)
dt
= k3C1(t) − k4C2(t) . (2.10)
It is of special interest the case in which the radiotracer can enter the second compartment,
but does not leave. This is what happens for 18FDG cellular uptake. Due to the impossibility
of the molecule to follow the glycolytic pathway, 18FDG gets trapped inside the cell, which
mathematically implies k4 = 0. In this case, the analytical solution of the total radiotracer
concentration Ct (t) in tissue is:
Ct (t) = Ca(t) ⊗
(
K1k2
k2 + k3
e−(k2+k3)t +
K1k3
k2 + k3
)
(2.11)
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2.4.4 Blood flow, perfusion and extraction fraction
The 1TCM described above allows us to obtain the physiologically meaningful parameters K1
and k2 and, although MBF is not any of these parameters, it is indeed related with K1, as we
will see below.
The rate Jt , at which the radiotracer activity perfuses the tissue can be described (see Fig.
2.5) as the difference between the arterial flux (Ja) and the venous (JV ). If the radiotracer does
not accumulate in tissue, then, Fick principle establishes that:
Jt = Ja − JV , (2.12)
where Ja and JV are defined as the product between the blood flow (F‡) and the arterial and
venous radiotracer concentration respectively (Ca and CV ):
Ja = FCa (2.13)
JV = FCV . (2.14)
Thus, Eq. 2.12 becomes:
Jt = F (Ca − CV ) . (2.15)
The unidirectional first-pass extraction, E , is defined as the fraction of tracer that travels from
the capillaries into tissue on a single pass, and is equal to:
E =
Ca − CV
Ca
. (2.16)
Eqs. 2.15 and 2.16 can be combined to express J in terms of the blood flow, the extraction
Figure 2.5: Tracer flow through a capillary. Ca and CV denote the radiotracer concentration in arterial and
venous blood, respectively. The radiotracer enters into the capillary with a flux Ja and leaves it by tissue extraction
(Jt) and venous circulation (JV ). This illustration was reproduced from [149].
.
‡This term, F, receives different names when referring to perfusion of a particular tissue, such as Pulmonary
Blood Flow (PBF) or Myocardial Blood Flow (MBF).
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fraction and arterial blood radiotracer concentration:
J = K1CA = (F · E)CA , (2.17)
which means:
K1 = F · E . (2.18)
This extraction fraction can be modeled [39, 175] in terms of the capillary permeability-
surface product (PS) and the blood flow (F) itself:
E = 1 − e−PSF . (2.19)
In the particular case of E = 1, tissue perfusion and blood flow are exactly the same phys-
iological parameter, since, in this case, all blood flowing through the capillaries perfuses the
tissue.
2.4.5 Diffusible tracers and extracellular volume
Extracellular volume fraction (ECV) is, as detailed in section 2.3, another physiological parameter
that becomes of great importance when assessing myocardial viability. This parameter can also
be obtained from compartmental model analysis of a diffusible tracer that cannot pass through
the cellular membrane. In such situation, ECV equals the so-called volume of distribution (VT ),
defined as the ratio between the radiotracer concentration in a region of the target tissue and in
blood (Ct/Ca) at equilibrium [76]. Being at equilibrium means that there is a null net radiotracer
flux between blood and tissue (Jt = dCt/dt = 0). Then, using Eq. 2.7:
0 = K1Ca − k2Ct → CtCa = ECV =
K1
k2
. (2.20)
2.5 Myocardial segmentation in cardiac PET
PET is an imaging technique and, as for every imaging technique, the resultant images are a com-
position of small picture elements (pixels). Every pixel is geometrically associated with a spatial
(and time, in case of dynamic PET scans) coordinate. In the particular case of three-dimensional
(tomographic) imaging techniques, such pixels are denoted as volume elements (voxels). The 3D
positions associated with every voxel are spatially ordered following three predefined planes: ax-
ial, sagittal, and coronal (see Fig. 2.6A). These planes have an anatomical meaning; the axial
plane divides the body into cranial and tail portions; the coronal plane divides it into dorsal and
ventral, and the sagittal plane divides it into left and right. However, they lose their utility when
the protagonist is the heart, since cardiac axes are not parallel to the body axes, and hence, the
anatomical planes do not clearly transect the ventricles or atria.
Over the years, many attempts have been done to define standards for plane selection and
orientation display for serial myocardial slices generated by 2D or 3D imaging. Eventually,
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Figure 2.6: A: Axial, sagittal and coronal slices of a contrast-CT of the thorax of a pig. These slices correspond
to the anatomical planes. B: Short-axis, vertical long-axis and horizontal long-axis orientations referred as cardiac
planes. (Illustrations of the anatomical and cardiac planes were obtained from [33]).
a consensus was made for the nomenclature, segmentation and assignment of coronary artery
territories [34] and all the analyses presented in this thesis follow those recommendations. Thus,
a brief description (extracted from [34]) is provided here:
2.5.1 Heart orientation
The consensus in research and clinical patient management displays parallel and normal planes
relative to the long axis of the left ventricle. This axis transects the apex and the center of the
mitral valve plane. Therefore, as a recommendation, all cardiac imaging modalities should orient
the heart using the long axis of the left ventricles as a reference.
2.5.2 Cardiac planes
The nomenclature of these planes are: short, vertical long-axis, and horizontal long-axis. In that
way, the vertical long-axis view approximates the apical 2-chamber echocardiographic view (in
which left ventricle and left atrium are displayed simultaneously), and the horizontal long-axis
view approximates the apical 4-chamber view (in which the four heart cavities are displayed at
the same time) (see Fig. 2.6B).
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2.5.3 Left ventricular segmentation
This approach divides the muscle of the left ventricle into a variable number of segments. Al-
though different models have been proposed depending on the desired application, the most
common model employed in cardiac nuclear PET imaging is the 17-segment model. This model
provides the best agreement with the available anatomic data and creates a distribution of 35%,
35% and 30% for the basal, mid-cavity and apical thirds of the heart.
For a correct segmentation, the left ventricle should be equally divided in thirds which are
perpendicular to the long axis of the heart. This will generate three circular slices of the left
ventricle: basal (from the mitral annulus to the tips of the papillary muscles), mid-cavity (a
region that includes the entire length of the papillary muscles) and apical (beyond the papillary
muscles until cavity ends) short-axis. These slices will be further divided in 6, 6 and 4 segments
respectively, being segments 1-6 related to basal slice, 7-12 to mid-cavity and 13-16 to apical
slice. The 17th segment will correspond to the apical cap (see Fig. 2.7).
Figure 2.7: Myocardial segmentation into territories and segments. A: illustration of the heart with its three
main coronary arteries (image modified from [114]). B: Left ventricular segmentation into basal, mid-cavity and
apical slices plus apical cap segment. C: Bullseye representing the 17-segment model. Green, blue and pink regions
correspond to myocardial territories irrigated by LAD, RCA and LCX coronary arteries respectively.
2.5.4 Assignment of segments to coronary artery territories
There is a significative variability in the coronary artery blood supply to myocardial segments.
Thus, some of the segments are sometimes assigned to one or other arterial territory. In this
work we have followed the most common convention. Fig. 2.7 shows the assignment of each
segment to the territories corresponding to LAD, RCA and LCX blood supply employed in this
work.
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3
MYOCARDIAL BLOOD FLOW DETERMINATION WITH 68GA-DOTA-PET
3.1 Introduction
Among the many applications of PET in nuclear medicine, myocardial perfusion imaging (MPI)
arises as the gold standard tool for noninvasive assessment of coronary artery disease (CAD) [48].
CAD is the leading cause of morbidity and mortality and a major source of disability worldwide
[21]. Hence, its accurate diagnosis becomes important in risk stratification and selection of
an appropriate management strategy. A complete assessment of known or suspected CAD must
include not only anatomical but functional evaluation, and this can be done by many noninvasive
imaging modalities such as CMR, SPECT and PET among others. SPECT is currently the
preferred clinical tool to perform MPI, with an utilization ratio of more than 10:1 with respect to
PET. However, although reliable, the information provided by SPECT is qualitative or, at most,
semi-quantitative, and the technique itself presents limitations such as long imaging protocols,
poor image resolution or reduced specificity due to attenuation artifacts. Altogether, these
limitations may translate into an underestimation of the degree of ischemia, especially in case
of multivessel disease [23]. On the other hand, PET provides an absolute quantification with
better spatial resolution, faster imaging protocols, and lower radiation doses received by patients.
On the top of that, PET also has higher sensitivity and specificity for detection of CAD [85].
However, although PET superior diagnostic accuracy over SPECT is well known and widely
recognized, and despite PET is considered the gold standard in CAD detection, the adoption of
cardiac PET has not been widespread.
The main reason for the underutilization of PET in the MPI field is the higher cost of a
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PET/CT scanner (about 4-5 times more expensive than a SPECT gamma camera) and, more
importantly, the reduced availability of the needed radiotracers. At present, the most utilized
radiotracers for MPI in PET are 13NH3, 82Rb and H215O [189]. However, their short half-life
(t1/2(13N) = 9.97 min, t1/2(15O) = 122 s, t1/2(82Rb) = 75 s) limits widespread clinical use due
to the need of a nearby cyclotron (13N and 15O) or expensive and dedicated generators (82Rb).
More recently, as stated in Chapter 1, Flurpiridaz, which is based on labeled 18F [155, 225], has
appeared as a good candidate. This tracer is currently in late stages of FDA approval and shows
potential to spread the use of PET for MBF image as its production does not depend on an on-
site cyclotron or generator. Nonetheless, the relatively long half-life of 18F (∼110 min) involves
much prolonged studies for sequential rest-stress tests and it still would require the existence of
a local cyclotron. The radiotracers named above are, essentially, the main agents used for PET
MPI. Although they are all well-established radiotracers, the necessity of a widely available and
low-cost probe, with an adequate half-life, has not been fulfilled yet.
However, in the past years, 68Ga has emerged as an alternative radioisotope. 68Ga is
a positron emitting radioisotope that is continuously available at a reasonable cost from a
68Ge/68Ga (68Germanium/68Gallium) generator [30]. This system is particularly attractive due
to the long half-life of the parent 68Ge (271 d) combined with a suitable half-life of the daughter
68Ga (68 min) for its use in clinical studies. Lately, several 68Ga-labeled radiopharmaceuti-
cals have been used in clinical PET studies [195], mainly in the field of neuroendocrine tumor
and prostatic cancer imaging. But despite several attempts, the development of 68Ga-labeled
radiopharmaceuticals suitable for MBF imaging has not yet succeeded [206].
More recently, Autio et al. proposed the novel radiotracer 68Ga-DOTA for assessment
of blood flow in experimental inflammation using a rat model [11]. The radioisotope 68Ga,
chelated with DOTA was hypothesized to behave as its analogue probes based on gadolinium
(Gd-DOTA and Gd-DTPA∗), which are widely used for contrast-enhanced CMR [121]. Following
the hypothesis of Autio et al., if the Gd-based contrast agents succesfully work as probes in CMR,
68Ga-DOTA may function as a probe for assessment of myocardial blood flow by PET. If so,
this novel compound may become a promising tracer in cardiac PET imaging, due to its low
production cost and high availability.
3.2 Aim of the chapter
In this chapter, we propose the use of 68Ga-DOTA as a new MPI tracer for in vivo PET assess-
ment of MBF. We evaluated the feasibility of this radiotracer as a new myocardial perfusion agent
in healthy pigs. To do so, a set of eight pigs was scanned under rest and (pharmacologically-
induced) stress, mimicking the conditions under which these tests are performed in clinical rou-
tine.
In addition, the absolute MBF values obtained with 68Ga-DOTA-PET were validated using
fluorescent microspheres (MS) [74], which is the accepted (but highly invasive) gold standard for
∗2-[Bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid.
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perfusion quantification due to the predictable behavior of the MS in the vascular bed.
3.3 Methods
3.3.1 Tracer production
68Ga (t1/2 = 68 min) was available from a 68Ge/68Ga generator system (ITG Isotope Technolo-
gies, Garching GmbH, Germany). 68Ga was eluted with 4 ml of 0.05 M HCl and added to a
solution containing 200 µg of DOTA dissolved in 0.25 M HEPES buffer pH 4.5. The mixture
was heated at 95 ◦C for 20 min. Finally, 90 µl of NaOH 1 M and 5 ml of NaCl 0.9% were added
yielding 68Ga-DOTA with a radionuclide purity at radio-HPLC† > 95%. About 200–600 MBq
of 68Ga-DOTA were obtained from each reaction, depending on the age of the generator.
3.3.2 Study design and animal preparation
The experiments were performed in a group of animals consisting of eight healthy Large White
pigs (4 females and 4 males, mean weight 38.8 ± 6.9 kg). The study was conducted according
to the guidelines of the current European Directive and Spanish legislation and approved by the
regional ethical committee for animal experimentation. Briefly, anesthesia was induced by in-
tramuscular injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam (0.5 mg/kg),
and maintained by continuous intravenous infusion of ketamine (2 mg·kg−1·h−1), xylazine (0.2
mg·kg−1·h−1), and midazolam (0.2 mg·kg−1·h−1). During the entire procedure the animals were
ventilated with 50%/50% oxygen/air mixture. Prior to the imaging session, the animals under-
went a catheterization procedure in the fluoroscopy room. A 5-French Judkins-Left catheter was
inserted into the left ventricle (LV) from the right femoral artery. A 1.8–2.6-French coronary
micro-guide catheter (Finecross MG, Terumo Medical Corporation, Somerset, NJ, USA) was
passed through the aforementioned catheter and guided to the left atrial appendage (LAA) of
the heart. This micro-guide catheter served to deliver the fluorescent microspheres used for the
MBF validation right into animal’s left atrium. This procedure revealed as a critical step in the
experimental protocol; only in case of a successful placement of the micro-guide catheter inside
the LAA, the experiment could be continued. The positioning of the catheter was done under
fluoroscopic guidance, using a Veradius mobile C-arm (Philips Healthcare, Best, The Nether-
lands). An illustrative image of the micro catheter placement in the LAA can be observed in the
Fig. 3.1.
Once the micro-guide catheter was placed in the LAA, the animals were moved to the
PET/CT imaging room. From that moment, oxygen saturation levels via pulse oximetry, heart
rate (HR), non-invasive systolic and diastolic arterial pressure, and electrocardiogram signal
(ECG) were monitored until the end of the study. The animals were scanned under three dif-
ferent physiological conditions covering a broad range of MBF values. For that purpose, three
dynamic 68Ga-DOTA-PET/CT scans were performed sequentially on each animal with 30 min-
utes delay between the beginning of consecutive PET scans (Fig. 3.2). The first scan was
†High performance liquid chromatography.
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Figure 3.1: A: Fluoroscopy image of the cardiac catheterization performed on one of the animals.The Judkins-
Left catheter enters the LV from the aorta and the tip of the micro-guide catheter leaves the bigger one and enters
the LAA (yellow arrow). B: Maximum intensity projection (MIP) of a contrast CT performed on the same animal
at the end of the imaging session. One of the objectives of the contrast-CT scan was to assess the position of the
micro-guide catheter at the end. If the tip remained inside the LAA, it was assumed that the microspheres were
delivered in the correct place.
Figure 3.2: A: Schematic drawing of the study approach. B: Scheme of experimental protocol followed during
MBF validation studies represented as a timeline. Colored boxes show time periods where every action was being
performed. The timeline is superimposed on a schematic AIF (dashed line). ADO stands for adenosine and CGS
stands for CGS-21680.
performed at resting condition. A second scan was performed under pharmacological stress
induced with adenosine (400–600 µg·kg−1·min−1, Sigma-Aldrich, Tres Cantos, Madrid, Spain).
Adenosine was infused intravenously for 6 minutes, starting 3 minutes before radiotracer injec-
tion. Since adenosine mediates coronary microvascular dilation mainly through adenosine A2A
receptor activation [84], we also used the selective A2A receptor agonist CGS-21680 (Santa Cruz
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Biotech. Inc., Dallas, TX, USA) in order to reach higher and longer lasting MBF values. There-
fore, a third scan was performed under pharmacological stress induced with CGS-21680 (10–15
µg/kg), administered as an intravenous bolus injection 3 minutes before radiotracer injection.
Radiotracer was injected simultaneously to the injection of 15 µm fluorescent microspheres (MS)
(FluoroSpheres R©, Molecular Probes, Eugene, OR, USA) consisting of 106 beads diluted into 10
ml of saline containing 0.01% Tween 80‡ to avoid aggregation. A different MS color was used on
each of the injections performed on the same animal including green (λ = 450/480 nm), yellow
(λ = 515/534 nm), and blue (λ = 365/415 nm). Immediately before MS dilution, the vial was
vigorously vortexed for 15 seconds, sonicated for 4 minutes and vortexed again for additional 15
seconds. MS were manually injected over ∼60 seconds directly into the LAA. A 16-ml arterial
blood reference sample was withdrawn from the femoral artery starting 1 minute before MS
injection at a constant rate of 5 ml/min. Additionally, a 2-ml blood sample was taken from the
coccygeal artery for hematocrit determination. An average hematocrit value of 0.29 ± 0.02 was
obtained.
3.3.3 PET image acquisition
PET/CT images were acquired using a Gemini TF-64 scanner (Philips Healthcare, Best, The
Netherlands). Each imaging study consisted of a low dose CT scan (120 kV, 80 mA) followed by a
dynamic 11-min list mode PET acquisition in a single bed position. 68Ga-DOTA (115 ± 27 MBq)
was prepared in 6 ml and infused at a rate of 1.0 ml/s through a marginal ear vein, followed by a
6 ml saline flush at the same rate. PET scans started 1 min prior to the radiotracer injection. At
the end of each imaging session, a contrast CT (1.2 ml/kg, Iomeron 400, Bracco, Milan, Italy) was
performed to obtain better anatomical delineation and to confirm that the micro-guide catheter
did not leave the LAA (see Fig. 3.1B). PET images were reconstructed with a voxel size of 4 ×
4 × 4 mm3 using a 3D-RAMLA reconstruction algorithm in 42 consecutive frames (1 × 60 s, 15
× 2 s, 8 × 5 s, 8 × 10 s, 1 × 20 s, 3 × 30 s, 1 × 40 s and 5 × 60 s). All corrections for decay, dead
time, scatter and random coincidences were applied as implemented on the scanner.
3.3.4 PET data analysis
Metal chelates have been widely used in MRI as contrast agents as they distribute in the blood
and the extracellular extravascular space [1]. Therefore, we assumed that 68Ga-DOTA diffuses
bidirectionally between the intravascular and the interstitial space and used a single-tissue com-
partment model (1TCM). The resulting tissue activity concentration derived from this 1TCM
model can be written as:
Ct (t) = F
1 − H · K1 · AIF(t) ⊗ e
−K1 ·t
ECV , (3.1)
where Ct (t) is the time activity curve (TAC) for the myocardial tissue, K1 is the unidirectional
transfer rate from blood to tissue (which can be further defined as the product of the extraction
fraction and the plasma flow [201], as explained in section 2.4, page 20), ECV is the volume
fraction of the extravascular extracellular space, H is the hematocrit, and F is the fraction of free
‡Also known as polysorbate 80; a nonionic surfactant used to maintain the microspheres in suspension
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tracer in plasma. Lastly, AIF(t) is the arterial input function, which is obtained from the image,
particularly from the descending aorta, in order to minimize the effects of statistical noise [212].
Eq. 3.1 describes the bidirectional diffusion of 68Ga-DOTA in myocardial tissue in an ideal
situation in which the two compartments (the plasma input and the tissue) are perfectly isolated
and separated from the rest of the anatomical structures of the heart. However, PET imaging
relies on a voxelized analysis of the ROI, and due to the poor spatial resolution of PET, these
voxels are large regions (in our case 4 × 4 × 4 mm3) in which all these anatomical structures
(tissue, blood pool and arterioles and venules from the capillary bed) coexist [13]. Hence, activity
concentration measured inside any voxel or TAC of our ROI could come from the tissue but also
from blood. To take into account this spilled-over activity, Eq. 3.1 can be modified as follows:
Ct (t) = F
1 − H · K1 · AIF(t) ⊗ e
−K1 ·t
ECV + VLV · CLV(t) + VRV · CRV(t) , (3.2)
where CLV(t) and CRV(t) are the TACs for the left and right ventricles respectively, and VLV and
VRV are the parameters that represent the spill-over fraction for the LV and RV [158].
These CLV(t) and CRV(t) terms were added to the Eq. 3.1 under the assumption that the
activity concentration inside each ventricle is well mixed and spatially homogeneous. However,
in our experimental studies conducted in pigs, we found differences in activity concentration
during certain timeframes within different LV regions, as can be seen in Fig. 3.3. Nevertheless,
as shown in the Fig. 3.4, the different behavior of the TACs measured in those ROIs cannot be
explained as a simple time delay between curves, since the delay is only observed in the rising
time. This is the reason why including an additional parameter related to time delay might not
be optimal. To overcome this issue, the contribution of both apical and central LV were included
in the model:
Ct (t) = F
1 − H · K1 · AIF(t) ⊗ e
−K1 ·t
ECV + VAP · CAP(t) + VLV · CLV(t) + VRV · CRV(t) , (3.3)
where CAP(t) denotes the TAC inside an apical region of the left ventricle, and now CLV(t)
does only account for the TAC inside its central region. This way, VLV, VAP and VRV are the
definitive parameters that represent the spill-over fraction for the central LV, apical LV and RV
respectively.
AIF was obtained from an 8 mm diameter cylindrical volume of interest (VOI) drawn in the
descending thoracic aorta over 5 consecutive slices [212]. CLV(t) and CAP(t) were obtained from
spherical VOIs drawn at the central (15 mm diameter) and apical (12 mm diameter) regions of
the LV respectively, while VOI for determination of CRV(t) was manually drawn inside RV over
3-5 slices leaving a margin (> 5 mm) from the myocardium. Spill-out from the AIF was corrected
normalizing to the average CLV(t) of the latest frames.
Time activity curves (Fig. 3.5) were fitted voxel-wise including the 5 model parameters
(K1, ECV, VLV, VRV and VAP) and obtaining parametric maps of K1 and ECV. Polar maps
were generated using available software [157]. The standard American Heart Association (AHA)
17-segment model [34] (detailed in section 2.5, page 23, was applied to determine regional val-
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Figure 3.3: Vertical long-axis (two-chamber) and horizontal long-axis (four-chamber) views of the first frames
of an illustrative dynamic PET in which the tracer, 68Ga-DOTA has been injected into a pig. The two circles
denote two spherical volumes of interest (VOIs) in which PET intensity was quantified. These VOIs correspond
to the middle of the LV (yellow) and an apical region of the LV (black). The PET images are fused with their
corresponding view of the contrast CT scan.
ues of K1 and ECV. Furthermore, average values were obtained for the three major coronary
artery territories: left anterior descending (LAD), left circumflex (LCX), and right coronary
artery (RCA). Average values were also computed for the whole myocardium. In order to obtain
MBFPET values, K1 should be corrected according to the extraction fraction of 68Ga-DOTA. For
that purpose MBFMS and K1 values obtained in healthy pigs averaged on the whole myocardium
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Figure 3.4: Activity concentration measured inside VOIs drawn in Fig. 3.3 presented as a function of time. It
can be noticed that these two curves follow different patterns. At early timeframes, activity concentration is higher
inside the central region of the LV. However, activity concentration decreases at the same time inside both areas.
Figure 3.5: Time activity curves (TACs) obtained for an exemplary 68Ga-DOTA PET/CT study, including
tissue (Ct (t)), left ventricle (CLV(t)), apical left ventricle (CAP(t)), right ventricle (CRV(t)) and PVC-corrected
arterial input function (AIF(t)) obtained from the descending thoracic aorta.
were fitted to the generalized Renkin-Crone model [39, 175]:
K1 = MBF ·
(
1 − a · e− bMBF
)
, (3.4)
where a accounts for the dependence of MBF with the permeability-surface product (PS ), and
b reflects the basal value of PS.
3.3 Methods 33
3.3.5 Microspheres analysis
MS recovery and analysis were based on existing protocols [193]. Briefly, the day after imaging
session, the animal was euthanized by an intravenous overdose of pentobarbital. The heart was
excised and kept at -20◦C for 3 hours. Left ventricular myocardial wall was then isolated and
sliced following AHA guidelines (see Fig. 3.6). A total of 17 pieces per heart were obtained,
Figure 3.6: Photographs taken during the heart processing done to obtain the 17 segments of the left ventricular
myocardium. The division into these segments was intended to be as accurate as possible, following the guidelines
provided by [34], and are shown as a schematic drawing in this figure.
weighted with a digital precision scale and individually digested into a KOH 4N solution (5 ml
KOH per gram of tissue). At the same time, each reference blood sample withdrawn during the
experiment was taken to 40 ml with 2% Tween 80, followed by addition of 14 ml of KOH 16N.
All samples were incubated at 37 ◦C with vigorous shaking for 48–72 h. After complete tissue
digestion, samples were individually filtered with negative pressure filtration. A different filter
(Nylon Net Filter 10 µm, Millipore, Burlington, MA, USA) was used for each sample. Each
digested sample was poured onto the filter, and the containing tube was rinsed with ∼20 ml
of 2% Tween 80 to ensure the collection of all the MS. Next, the filter was rinsed with ∼10
ml of buffer rinse solution (KH2PO4/K2HPO4 at pH = 7.2) to neutralize the pH of the nylon
filter. Each filter was immersed in 5 ml of 2-ethoxyethyl acetate 98% (Sigma-Aldrich, Sant Louis,
MO, USA) and stored in the dark for 2–3 h, until the complete dissolution of the MS polystyrene
cover. The fluorescence of the resultant solution was measured with a Fluorescence Spectrometer
(PerkinElmer LS-55) at the emission/excitation wavelengths of 450/480 nm, 515/534 nm and
365/415 nm for the green, yellow and blue MS respectively. Both emission and excitation slits
were set at 10 nm. Finally, the fluorescence intensities of each sample were used to compute the
MBF (MBFMS) following the standard MS reference technique [58].
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3.3.6 Statistical analysis
For the validation of MBFPET, ordinary least-squares regression analysis was used to assess
correlation between MBFPET and MBFMS. This correlation was performed on the three main
coronary artery territories by averaging the segmental values obtained according to AHA guide-
lines. Null hypotheses of slope = 1.0 and y-intercept = 0.0 were assessed. To test agreement
between our proposed method against the gold standard, Bland-Altman plots [26] and intra-
class correlation coefficients (ICC (A,1)) for a two-way mixed effect model [137] were calculated.
Limits of agreement for both markers were set at 95% confidence level (mean ± 1.96 SD).
3.4 Results
3.4.1 Validation of MBFPET versus gold standard MBFMS
Average hemodynamic parameters measured during MS validation studies under each rest/stress
condition are shown in Table 3.1. During resting condition, HR was stable and within a normal
range, as well as systolic and diastolic blood pressure. Adenosine infusion caused tachycardia and
dysrhythmia for few minutes, after which HR stabilized to same rate as before infusion. Adeno-
sine also lowered blood pressure significantly during the same period. The selective A2A receptor
agonist CGS-21680 induced tachycardia but in contrast to adenosine, this was maintained (peak
HR increment of 70% at peak HR an 65% 10 min after CGS-21680 infusion). Illustrative records
of the HR of two animals that underwent pharmacological stress are shown in Fig. 3.7.
Figure 3.7: HR recorded during the whole imaging session of two different animals. The time at which either
adenosine (orange) of CGS (red) was delivered into the animals are marked by a colored dashed vertical line.
Green, orange and red boxes denote represent the time windows of the 10-min PET scans performed at rest and
under ADO- and CGS-induced stess.
A total of 24 PET scans were performed (n = 8 pigs, 3 studies each). Two studies were
discarded due to an incomplete extraction of arterial blood reference sample required for MBFMS
quantification. From the 22 remaining studies, regional MBFMS and K1 measurements were ob-
tained following AHA recommendations (the 17th segment, corresponding to the apical region,
was discarded in all analyses since K1 for this region was overestimated, maybe caused by spill-
over from the liver [81]). Resultant values were averaged into the three main coronary artery
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Table 3.1: Systemic hemodynamic parameters at baseline and different moments during hyperemia.
HR (bpm) Systolic BP (mmHg) Diastolic BP (mmHg)
Baseline 79 ± 21 122 ± 15 82 ± 7
3 min after ADO infusion 111 ± 31 (43.7) 80 ± 16 49 ± 12
10 min after ADO infusion 79 ± 19 (1.0) 118 ± 17 77 ± 9
3 min after CGS-21680 130 ± 22 (71.4) 75 ± 15 47 ± 12
10 min after CGS-21680 120 ± 17 (65.6) -a -a
Values shown as Mean ± SD. Values in parentheses show HR increment (in %) vs HR right before stress induction.
a No BP measurements were taken for 10 min after CGS-21680 injection.
territories, resulting in a total of 66 paired MBFMS and K1 values. Subsequently, paired measure-
ments were grouped to obtain an average value of the whole myocardium at each physiological
condition.
The fit of MBFMS and K1 values averaged on the whole myocardium to the generalized
Renkin-Crone model (a = 0.82 ± 0.08, b = 2.14 ± 0.28 ml·min−1·g−1, Fig. 3.8), resulted into
a first-pass tissue extraction fraction for 68Ga-DOTA of ∼70% when MBF takes values between
1.8 and 2.4 ml·min−1·g−1.
Figure 3.8: Scatter plot of K1 obtained by 68Ga-DOTA-PET against MBF obtained by fluorescent MS.
Each point represents the whole LV myocardium value obtained at different physiological conditions includ-
ing rest (green), ADO-induced stress (orange) and CGS-induced stress (red). The fit to the Renkin-Crone
(K1 = MBF · [1 − a · exp(−b/MBF)]) model is shown (dashed blue line) including the 95% confidence interval
of the regression line (dotted gray lines).
MBFPET values (mean ± SD) obtained with 68Ga-DOTA were 1.06 ± 0.33 ml·min−1·g−1 at
rest, 1.45 ± 0.67 ml·min−1·g−1 under adenosine-induced stress, and 2.55 ± 0.89 ml·min−1·g−1 under
CGS-induced stress. Fig. 3.9A shows a good linear correlation (r = 0.77) between MBFPET and
MBFMS (slope = 0.91 ± 0.08, significantly non-different from 1.0 (p = 0.25), y-intercept = 0.21
± 0.15 ml·min−1·g−1, significantly non-different from 0.0 (p = 0.16)) at the three main coronary
artery territories. Fig. 3.9C shows a strong correlation (r = 0.91) when MBFPET and MBFMS
are averaged over the whole myocardium: (slope = 0.96 ± 0.10, significantly non-different from
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1.0 (p = 0.30), y-intercept = 0.11 ± 0.19 ml·min−1·g−1, significantly non-different from 0.0 (p =
0.07)).
Figure 3.9: Scatter plots (A,C) and Bland-Altman plots (B,D) showing correlation between MBF estimated
by 68Ga-DOTA-PET and by fluorescent MS. Each point represents MBF in one of the three major coronary
artery territories (A and B), and in the whole LV myocardium (C and D). Scatter plots also contain the identity
line (dashed gray line) and the linear fit (solid line) including 95% CL (dotted lines). Datasets corresponding
to different physiological conditions are represented in different colors including rest (green), ADO-induced stress
(orange) and CGS-induced stress (red). Bland-Altman plots include the mean difference (solid gray line) and the
mean ± 1.96 SD (dashed gray lines).
3.5 Discussion
In this chapter, we proposed 68Ga-DOTA as an alternative radiotracer for in vivo imaging and
non-invasive assessment of MBF based on PET.
The in vivo validation of MBF values by 68Ga-DOTA-PET was performed on sequential
scans at rest and during different pharmacologically-induced stress conditions with a 30 min
delay between consecutive scans. The reader might question whether this delay is sufficiently
high to ignore the residual activity that may exist inside the animal after the first radiotracer
injection. The employed solution to kinetic equations assumes zero activity concentration in
tissue at initial time, which is not the case for second and third scans performed on the same
animal. However, the radiotracer was injected 1 min after PET scan started and only data
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after tracer injection was included to minimize the residual difference between the model and
the measured data. In this way, the time required by the model to equilibrate the tissue to its
initial value was excluded from the minimization process. The equations could be solved in more
general terms, but for simplicity we decided to use the standard solution since the employed
methodology provides the same results.
Our results demonstrate the feasibility of the proposed technique to reliably evaluate MBF
under different physiological conditions. Importantly, validation studies (Fig. 3.9) of the MBF
values obtained with 68Ga-DOTA-PET against the gold-standard – MS – showed a reasonably
good agreement when comparing an averaged MBF values over the three main coronary artery
territories (mean difference = 0.06 ± 0.59 ml·min−1·g−1, Fig. 3.9B) and over the whole my-
ocardium (mean difference = 0.06 ± 0.40 ml·min−1·g−1, Fig. 3.9D).
The extraction fraction for 68Ga-DOTA was estimated by fitting K1 and MBFMS values to
the Renkin-Crone model (Fig. 3.8). From this fit, a first-pass tissue extraction fraction of 70%
was estimated for 68Ga-DOTA for MBF values between 1.8 and 2.4 ml·min−1·g−1, which is in line
with those reported for other perfusion tracers like 13NH3 and 82Rb (80% and 65% respectively
[128]). However, the extraction fraction that we obtained for 68Ga-DOTA cannot be directly
compared with values reported for other tracers as obtained K1 is related to plasma flow instead
of blood flow as mentioned in the methods section and because partial volume correction was not
applied in the myocardial tissue. Therefore, the estimated tracer extraction function is based on
biased estimates of K1, and not likely applicable to other imaging conditions.
High accuracy of PET imaging has shown to be superior among all other MBF imaging
techniques, achieving the highest diagnostic performance [100, 185]. However, limited availability
of PET tracers for MBF, either due to the need for a nearby cyclotron (13NH3, H215O) or
because of the high cost of the 82Rb generators, precluded its further extension in the clinical
field. Alternatively, generators accessibility has made 68Ga widely available and 68Ga-based
tracers are increasingly used in nuclear medicine, e.g., to study neuroendocrine tumors and other
somatostatin receptor-associated lesions. Thus, the use of 68Ga-DOTA for MBF determination
could be an accessible alternative for accurate detection of CAD. However, further studies are
needed to identify the clinical potential of this tracer.
3.5.1 Study Limitations
The studies described in this work have been performed on a porcine model as it provides a
similar and comparable model of the human anatomy and pathophysiology. Results obtained
may not be directly extrapolated to clinical setting. Thus, clinical studies are needed to support
and underpin the results presented in this study.
Similar to H215O, 68Ga-DOTA does not provide high myocardial-to-blood ratio and it might
yield a suboptimal image quality and lower MBF defect contrast. However, validation results
performed at each coronary territory show reasonably good agreement with reference MS val-
ues (see Fig. 3.9) supporting the potential clinical use of 68Ga-DOTA-PET for non-invasive
quantitative determination of regional MBF.
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3.6 Conclusion
The proposed 68Ga-DOTA-PET imaging technique has shown potential for non-invasive assess-
ment of MBF. The absolute MBF values obtained at rest and during different pharmacologically-
induced stress conditions covering a broad range of MBF values in healthy pigs were validated
using the gold standard (MS). This tracer could provide wide clinical use of high accuracy PET
imaging for MBF measurements regardless of the availability of expensive in-house cyclotrons
or 82Rb generators. Our results show potential for the clinical implementation of this technique
and suggest the necessity to perform clinical studies that explore its possible application in the
clinical field.
4
VIABILITY ASSESSMENT IN A MYOCARDIAL INFARCTION MODEL
4.1 Introduction
In the previous chapter, we proposed and validated 68Ga-DOTA as a new MPI tracer for in
vivo PET assessment of MBF. As we previously stated, MPI gives insight of how well the heart
muscle is perfused. However, perfusion assessment is only a part of the information needed in
risk stratification of patients with known or suspected CAD. The missing piece of information
is the myocardial viability. It has been demonstrated that there is an association between
myocardial viability and improved survival after revascularization in patients with chronic CAD
and LV dysfunction [3, 47, 77], and only patients with dysfunctional but viable myocardium may
potentially benefit from revascularization [134]. Therefore, the quantification and assessment of
myocardial viability becomes of utmost importance to optimize selection of patients with heart
failure.
PET is one of the most sensitive techniques to assess cardiac viability. Particularly, FDG-
PET has been shown to be highly specific in distinguishing viable from non-viable or scarred
myocardium [138] by characterizing dysfunctional cardiomyocytes. The myocardial cells tend
to obtain energy from free fatty acids in a normal heart during fasting. However, in periods
of ischemia or after a meal, the main source of energy switches to glucose (glycolysis). Hence,
FDG-PET is able to distinguish between scarred (low glucose uptake) and viable (normal glucose
uptake) myocardium [2].
Apart from glucose metabolism, myocardial viability can be determined by quantification of
the extracellular volume fraction (ECV) using late gadolinium-enhancement (LGE)-MRI [211],
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which identifies increased extracellular space in areas of infarction and scar. Recently, it has
been shown the capability of 64Cu-DOTA for the assessment of myocardial viability using PET
imaging [108] in analogy to LGE-MRI. In addition, other PET tracers typically used only for
MBF assessment have been proposed to evaluate myocardial viability [146].
In the previous chapter we introduced the pharmacokinetic model that rules biodistribution
of 68Ga-DOTA in the myocardial tissue. From that model, MBF values could be easily obtained
from fits to dynamic PET data. Importantly, ECV values could also be computed from the same
fit. This fact would make 68Ga-DOTA a bimodal MBF (perfusion) + ECV (viability) radiotracer
with a high translational possibility.
4.2 Aim of the chapter
In this chapter, we propose the use of 68Ga-DOTA for in vivo PET imaging of ECV and MBF
simultaneously. In order to evaluate its feasibility, a myocardial infarction (MI) pig model was
employed. ECV and MBF derived within the infarcted areas of the hearts were compared with
those obtained from the remote ones, and the ability of 68Ga-DOTA to assess myocardial viability
was studied.
4.3 Methods
4.3.1 Study design and animal preparation
This study was conducted according to the guidelines of the current European Directive and
Spanish legislation and approved by the regional ethical committee for animal experimentation.
The study population consisted of a group of five young Large White pigs (3 females and 2 males,
mean weight = 47.9 ± 1.2 kg).
MI was induced by closed-chest ischemia/reperfusion. To do so, an angioplasty balloon was
placed into the left anterior descending (LAD) coronary artery, immediately distal to the origin
of the first diagonal branch, and occluded it for 40 minutes. Afterwards, the balloon was deflated,
and blood flow was re-established. A more detailed explanation of the MI protocol can be found
elsewhere [59, 66].
Anesthesia was induced by intramuscular injection of ketamine (20 mg/kg), xylazine (2
mg/kg), and midazolam (0.5 mg/kg), and maintained by continuous intravenous infusion of
ketamine (2 mg·kg−1·h−1), xylazine (0.2 mg·kg−1·h−1) and midazolam (0.2 mg·kg−1·h−1). Animals
were intubated and mechanically ventilated with oxygen (fraction of inspired O2: 28%). The
infarctions were confirmed and evaluated 7 days post-infarction by CMR immediately before
the 68Ga-DOTA-PET/CT studies. PET scans were performed at rest condition. A schematic
drawing of the experimental protocol is shown in Fig. 4.1.
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Figure 4.1: Workflow of the study approach.
4.3.2 CMR protocol and analysis
CMR scans were performed in the infarcted pigs prior to the PET/CT studies with a 3-T Achieva
Tx whole body scanner (Philips Healthcare, Best, The Netherlands) equipped with a 32-element
phased-array cardiac coil. The imaging protocol included a standard segmented cine steady-state
free-precession (SSFP) sequence to provide high quality anatomical references, and assessment of
LV mass, wall thickness and left ventricular ejection fraction (LVEF). The imaging parameters
for the SSFP sequence were field of view (FOV), 280 × 280 mm2; slice thickness, 6 mm with no
gap; repetition time (TR), 2.8 ms; echo time (TE), 1.4 ms; flip angle, 45◦; cardiac phases, 30;
voxel size, 1.8 × 1.8 mm2; and number of excitations (NEX), 3.
To assess infarct size, pigs received intravenous gadopentetate dimeglumine contrast agent
(0.40 mmol per kg body weight), and contrast-enhanced imaging (late gadolinium enhancement
(LGE)) was performed after 10 to 15 min using an inversion-recovery spoiled turbo field echo
(IR-T1TFE) sequence with the following parameters: FOV, 280 × 280 mm2; voxel size, 1.6 × 1.6
mm2; end-diastolic acquisition; thickness, 6 mm with no gap; TR, 5.6 ms; TE, 2.8 ms; inversion
delay time optimized to null normal myocardium and 2 NEX. CMR images were analyzed using
dedicated software (QMassMR 7.6, Medis, Leiden, The Netherlands) by an experienced observer
in CMR analysis [60]. Wall thickening measurements were performed using a clinical standard
method in the Balance-TFE 1.8 mm sequence, which consisted on tracing endo and epicardial
contours both in systolic and diastolic phases in all the segmented LV.
CMR-derived infarct size was derived using endo and epicardial contours delineated in the
LGE sequence. Then, two regions of interest (ROIs) were placed in both the remote and the
hyperintense (infarcted) areas (see Fig. 4.2). Finally, infarct size was determined as the fractional
area occupied by the hyperintense ROI with respect to the total.
4.3.3 PET image acquisition
PET/CT images were acquired using a Gemini TF-64 scanner (Philips Healthcare, Best, The
Netherlands). Each imaging study consisted of a low dose CT scan (120 kV, 80 mA) followed
by a dynamic 11-min list mode PET acquisition in a single bed position. 68Ga-DOTA (139 ±
37 MBq) was prepared in 6 ml with normal saline and infused at a rate of 1.0 ml/s through a
marginal ear vein, followed by a 6 ml saline flush at the same rate. PET scans started 1 min
prior to the radiotracer injection. At the end of each imaging session, a contrast CT (1.2 ml/kg,
Iomeron 400, Bracco, Milan, Italy) was performed to obtain better anatomical delineation. PET
images were reconstructed with a voxel size of 4 × 4 × 4 mm3 using a 3D-RAMLA reconstruction
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Figure 4.2: Heart short-axis view of one of the animals in our MI model obtained with the LGE-CMR protocol.
The image is a screenshot of the software utilized to quantify infarct size. Endocardial (red) and epicardial (green)
contours are manually delineated. The software automatically marks as enhanced myocardium the signals with >
6 SD above mean of remote ROI intensity (measured inside orange ROI).
algorithm in 42 consecutive frames (1 × 60 s, 15 × 2 s, 8 × 5 s, 8 × 10 s, 1 × 20 s, 3 × 30 s, 1 ×
40 s and 5 × 60 s). All corrections for decay, dead time, scatter and random coincidences were
applied as implemented on the scanner.
4.3.4 PET data analysis
PET scans were analyzed following the pharmacokinetic model presented in the previous chapter
(section 3.3.4, page 29), as the employed tracer and the tissue of interest are both the same. As
before, AIFs were obtained from the images, from 8 mm diameter cylinders manually drawn
inside 5 consecutive slices of the descending aorta. The rest of VOIs needed for the analysis
(RV and LV from central and apical areas) were also drawn as explained in the previous chapter
(page 30).
The TACs measured over the left ventricular myocardial wall were fitted voxel-wise to Eq.
3.3 (page 30), leading to parametric maps of ECV and K1. These maps were converted into the
standard 17-segment model polar maps using dedicated software [157]. Regional values of ECV
and K1 were determined in a segmental (17 AHA segments) and territorial (LAD, LCX, RCA)
basis. K1 values were converted to MBFPET by using Renkin-Crone model (Eq. 3.4, page 30)
with the parameters obtained in our validation studies.
PET-derived infarct size was computed using ECV polar-plots obtained from 68Ga-DOTA
PET scans as the percentage of the total myocardial LV with abnormally elevated ECV, consid-
ered to be greater than mean + two standard deviations over ECV calculated in healthy animals.
This threshold (mean + 2 SD) was calculated from ECV maps obtained from the healthy ani-
mals used in the previous study. Afterwards the ECV polar-plots obtained from these infarcted
animals were masked, and total infarcted area was computed with the voxels which presented
ECV below the preset threshold.
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4.3.5 Statistical analysis
Unless otherwise stated, data are expressed as median and interquartile ranges in the follow-
ing manner: median(25th percentile; 75th percentile). As for MI model, MBFPET and ECV
were compared on the three main coronary artery territories averaging the segmental values ob-
tained according to AHA guidelines. These three regions were compared two-by-two by unpaired
Mann-Whitney t-test after studying normality of populations with D’Agostino & Pearson nor-
mality test. Independence between the three populations was assessed by Pearson correlation.
F test was used to compare variances and Welch’s correction was applied when the variances
inside a population were significantly different. In all analyses, p-values < 0.05 were considered
statistically significant.
4.4 Results
4.4.1 Infarct assessment by CMR and PET
Table 4.1 shows functional values obtained by CMR for the five animals of the study. (Mean ±
SD) LV mass values assessed by LGE-CMR were 69.1 ± 5.5 g, with a mean infarct mass of 22.2
± 6.0 g, which represents the (32.0 ± 7.4)% of the total LV mass. Mean LVEF obtained with cine
sequence was (40.2 ± 6.4)%. PET-derived infarct size assessed as percentage of myocardial LV
volume with ECV > 0.45 (2 SD above the mean ECV values obtained in healthy animals) was
(34.3 ± 14.1)%, which is not significantly different from mean infarct size assessed by LGE-MRI
((32.0 ± 7.4)% , p < 0.0001).
Table 4.1: Functional values obtained by CMR.
Animal # LVEF (%)a LV mass (g) IS (g)b IS (%)
1 33.75 76.01 27.58 36.28
2 31.62 73.86 30.17 40.84
3 46.35 67.66 13.74 20.31
4 47.43 67.47 18.17 26.92
5 41.59 60.44 21.44 35.48
a LVEF : Left ventricular ejection fraction.
b IS : Infarct size.
Wall thickening (expressed as diferrence between LV wall thickness in systole and diastole)
was (20 ± 17)%, (37 ± 19)% and (41 ± 25)% for LAD, RCA and LCX respectively. Fig. 4.3
provides an example of the analysis of wall thickening.
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Figure 4.3: Representative example of the wall thickening analysis. Endocardial contours were delineated in red,
epicardial contours in green. A bullseye graph was generated after the analysis with the percentual difference for
each of the 16 segments.
4.4.2 Regional ECV and MBFPET in MI
Fig. 4.4 shows the TACs measured in infarcted (LAD) and remote (RCA) regions of one of the
animals. The fits to the pharmacokinetic models corresponding to the activity concentration
in myocardial tissue are also shown. These TACs, along with their fits, show clear different
behavior, which is translated into different K1 values. The major difference is observed in the
shape of the curve when the tracer is entering the tissue (at the earliest time frames), with a
more pronounced peak at higher K1 values (see dashed lines in Fig. 4.4).
Figure 4.4: TACs (straight lines) measured inside ROIS segmented within LAD (black) and RCA (green) regions.
Dashed lines represent the activity concentration fitted in the myocardial tissue ROIs.
Fig. 4.5 shows short-axis LGE-CMR and PET parametric ECV and K1 images demonstrat-
ing the capability of this technique to distinguish regions with altered ECV and MBF in pigs
after MI. Parametric maps are fused with their corresponding contrast-CT images for visual-
ization purposes. In addition, polar plots obtained on infarcted pigs are shown in Fig. 4.6. A
decrease in the K1 is observed in the infarcted area (LAD) while ECV was increased.
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Figure 4.5: Representative short-axis LGE-CMR (top) and PET parametric K1 (middle) and ECV (bottom)
images obtained for the 5 MI model pigs. Parametric maps (smoothed with a median-3D filter, kernel size of 4)
are superimposed with the corresponding contract-CT image (except for pig #1, where contrast-CT image was not
available). Yellow arrows show enhanced areas observed by LGE-CMR.
Figure 4.6: Polar plots of K1 (top) and ECV (bottom) for the 5 pigs included in the myocardial infarction study.
These studies were performed at rest condition. A smoothing filter of 11 × 11 kernel size was applied.
Fig. 4.7 shows the quantitative ECV and MBFPET comparison between the infarcted and
remote regions. MBFPET values obtained with 68Ga-DOTA in the infarcted area were signifi-
cantly reduced in comparison to remote ones: infarcted (LAD): 0.36 (0.26 ; 0.57) ml·min−1·g−1 vs.
LCX: 1.35 (0.93 ; 1.48) ml·min−1·g−1, (p < 0.0001); and vs. RCA: 1.00 (0.54 ; 1.35) ml·min−1·g−1,
(p < 0.0001). ECV increased in the infarcted area (LAD: 0.49 (0.41 ; 0.51) vs. LCX: 0.30 (0.27
; 0.39), (p < 0.0001); and vs. RCA: 0.38 (0.31 ; 0.42), (p < 0.0001)).
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Figure 4.7: Scatter plots of MBFPET (A) and ECV (B) values observed in the three main coronary artery
territories for the 5 pigs included in the myocardial infarction study. Each dot corresponds to the averaged value
for every AHA segment excluding apex. These studies were performed at rest condition.
4.5 Discussion
In this study, we proposed an in vivo imaging technique for non-invasive assessment of MBF and
ECV based on 68Ga-DOTA-PET. We evaluated this technique in an experimental pig model of
myocardial infarction. The presence of an infarction in the LAD coronary artery of the animals
was visually confirmed from the very first moment with the LGE-CMR scan. The infarct size
depends on the time elapsed between the occlusion of the coronary artery and the reperfusion [82,
172], and a 40-min ischemia/reperfusion model is expected to provide large infarct sizes in the
animal. The five pigs had a large infarct size ((32.0 ± 7.4)% and (34.3±14.1)% assessed by CMR
and 68Ga-DOTA PET). Additionally, wall thickening showed to be diminished in this territory
((20 ± 17)%) while remained in normal values in RCA and LCX ((37 ± 19)% and (41 ± 25)%
respectively) and confirmed the presence of an infarction in the LAD. Wall thickening can be
defined as the difference of myocardial segment thickness during systole and diastole. It can be
presented in mm or as a percentage and is directly related to myocardial function abnormalities
and correlates to the extent of the infarct size [75, 122, 186]. Large wall thickening is expected
in a healthy myocardium, since myocardial wall is thickened during systole (when ventricles
contract) and thinned during diastole (when ventricles relax). However, infarcted myocardium
loses its contractile ability and wall thickening decreases significantly in the ischemic territory
[55, 90, 91, 196].
Absolute quantification of MBF can be used as a surrogate marker for coronary vascular
health and to monitor therapeutic interventions in patients with CAD [51]. In addition to MBF,
measurement of the ECV in the myocardium can be used to assess myocardial viability and
might be valuable to determine the development of fibrosis or edema related to CAD [211, 219].
Our results demonstrate the feasibility of the proposed technique to identify ischemic areas of the
myocardium by combined MBF and ECV measurements. Thus, infarcted areas on MI pigs were
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clearly identified (Figs. 4.5 and 4.6) supporting the potential clinical use of 68Ga-DOTA-PET for
non-invasive quantitative determination of regional MBF and ECV. As expected, MBF values
obtained with 68Ga-DOTA-PET in the infarcted areas were significantly reduced in comparison
to remote non-infarcted regions (see Fig. 4.7A). On the other hand, as it has been demonstrated
for this animal model, ECV was significantly increased in the infarcted areas in pigs 7-days
post-infarction [59].
Regarding Fig. 4.7, we found a notable difference for K1 pattern in animal #2 seems different
to the others. This could be associated to individual variability response to the experimental
procedure. Nonetheless, the relative pattern seems to be consistent with the other pigs, although
lower values are obtained. Thus, although perfusion values are found in the remote region, even
lower values are found in the infarcted region. Either lower initial perfusion at resting condition
or physiological differences among animals would explain this abnormality.
Furthermore, a different ECV pattern appeared in animal #1 of Fig. 4.7. We observed
that for this pig a larger spill-over from blood compartment was obtained, which might be the
consequence of some imprecision in the model or due to not appropriate delay or dispersion from
the AIF obtained from the descending aorta. However, as it was the only case in this study
where we observed this behavior, we could not made further conclusions.
Fig. 4.8 provides a deeper analysis for animal #1 where the AIF was delayed by different
amounts of time (0 to 10 seconds). This figure shows how the LAD values remain constant while
remote areas clearly differ. However, larger residuals were obtained for increased delays.
Figure 4.8: ECV (A) and K1 (B) results for TACs corresponding to the three main coronary artery territories
as a function of a delay implemented in the pharmacokinetic model. AIF is time-shifted according to the proposed
delay in order to account for the time difference between the moment when AIF is measured inside the DA and
the moment when the tracer arrives to the myocardial tissue.
This unexpected ECV pattern observed in animal #1 may also be indeed an accurate
measurement of the generalized increase of ECV that could actually be happening in this animal.
In fact, it has been reported that diffuse myocardial fibrosis is upregulated by many factors,
including remote post-infarct remodeling [184]. And the presence of this diffuse myocardial
fibrosis involves increased collagen content, and should increase ECV values [69, 211]. Hence,
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an increased ECV map in remote regions observed in animal #1 may be due to the presence
of diffuse fibrosis as a consequence of post-infarct remodeling. This subtle abnormality cannot
be observed with LGE-CMR as this technique only represents local regions of increased fibrosis,
but not diffuse fibrosis [147].
4.5.1 Study Limitations
Analyses of MBF and ECV on MI were performed including the entire coronary territories to
reduce observer-dependent variations. This approach could introduce some bias because the
entire myocardial LAD territory may have not been affected by ischemia. However, significant
differences of MBF and ECV between infarcted and remote areas were found, suggesting that a
more detailed segmentation of the infarcted area could result in even more significant differences.
Histological validation of ECV quantification was not performed in this work. However, a
recent study used histology and autoradiography to validate the ability of the chelating agent
used here (DOTA) labelled with a different isotope (64Cu-DOTA) to calculate the extracellular
volume fractions of fibrotic cardiac tissues, showing very good correlation with the PET results
[108].
The long ischemia/reperfusion protocol utilized in our model was conceived to generate a
large myocardial infarction that could provide large differences between ischemic and the remote
areas. Nevertheless, we hypothesized that 68Ga-DOTA PET could identify less focal scarring
due to the high sensitivity of the technique, but we have not yet performed studies on animals
with smaller or less focalized defects.
Further experiments should be performed in order to validate the application of this tech-
nique for ECV determination in different disease conditions including myocardial infarction and
diffuse myocardial fibrosis.
4.6 Conclusions
68Ga-DOTA PET imaging of animals with a MI model has been demonstrated as an effective
tool to assess significant differences in MBF and ECV between different territories of an ischemic
heart. Therefore, 68Ga-DOTA raises as an alternative to other existing PET tracers for the
assessment of MBF in a MI model. Moreover, 68Ga-DOTA-PET permits the simultaneous as-
sessment of myocardial viability in the same scan by measuring ECV. Thus, a rest-stress and
viability acquisition protocol could be performed within 30 minutes, considerably reducing the
scanning times required at present time.
5
PULMONARY BLOOD FLOW ASSESSMENT USING 68GA-DOTA-PET
5.1 Introduction
Thus far, we have presented 68Ga-DOTA as a new PET radiotracer that allows to perform MBF
and viability imaging studies. These imaging techniques play a crucial role in CAD management
and hence, 68Ga-DOTA appears as a promising MPI radiotracer.
However, there are many other diseases that could benefit from the high availability of a
perfusion tracer such as 68Ga-DOTA even when cardiac perfusion is not the target. Pulmonary
perfusion (pulmonary blood flow, PBF) plays also an important role in the evaluation of many
lung diseases like chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH)
or pulmonary embolism. These diseases are frequently described as lung diseases, but it is known
that there is a close relationship between heart and lung diseases [44, 80, 83]. In line with this,
for example, it is known that adults with congenital heart disease may develop PH [70], and
prolonged exposure to small particulate matter is closely related to atherosclerotis development
and heart disease [10, 183, 204].
In vivo determination of regional pulmonary blood flow (PBF) is a valuable tool for the
evaluation of the aforementioned lung diseases. Different imaging modalities have been suggested
to accomplish this task, including MRI [61, 97], scintigraphy [18], SPECT [17], CT [42] and PET
[191, 192].
Determination of PBF with PET using H215O is considered the clinical standard [143, 154,
176, 192], but the same argument used in the previous chapters could be given in this case;
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the short half-life of 15O and the fact that it requires an on-site cyclotron for its production
reduces enormously the availability of this technique. On the contrary, in vivo PET imaging
using 68Ga-DOTA as a radiotracer for PBF-PET imaging may open a new door in the field,
due to its promisingly low cost-effectiveness, ease of production and suitable half-life for clinical
studies.
An evaluation of the feasibility of 68Ga-DOTA as a PBF-PET radiotracer will be presented
next. To validate the results, we will simultaneously measure PBF with fluorescent microspheres
as well. Blood flow measurements with microspheres (MS) is considered to be the gold standard
[167] for the ex vivo validation of cardiac perfusion [155, 194], as we saw in Chapter 3, but
also for renal [118] , brain [29, 159] and soft-tissue tumor [106] perfusion imaging. In our case,
the MS technique will provide accurate quantitative regional PBF after removing the lung and
processing individual tissue samples.
5.2 Aim of the chapter
The purpose of this chapter is in line with that in Chapter 3, but this time we evaluated the
feasibility of using 68Ga-DOTA for in vivo PET imaging of regional PBF in pigs. We validated
the results using fluorescent MS as in the previous work.
5.3 Methods
5.3.1 Study design and animal preparation
As in every in vivo study presented in this thesis, the care and use-of-animals protocol was
followed according to the guidelines of the current European Directive and Spanish legislation,
and approved by the regional ethical committee for animal experimentation. This study was
performed on young Large White pigs of either sex (n = 4, mean weight = 41.9 ± 5.9 kg).
Anesthesia protocol followed was the same than the one followed in the previous chapters; animals
were sedated with a combination of ketamine (20 mg/kg), xylazine (2 mg/kg) and midazolam
(0.5 mg/kg) and kept anesthetized by intravenous infusion of ketamine (2 mg·kg−1·h−1), xylazine
(2 mg·kg−1·h−1) and midazolam (0.2 mg·kg−1·h−1) in saline. The animals were intubated and
mechanically ventilated in pressure support ventilation mode with mean fractional concentration
of oxygen in inspired gas of 35–40%, tidal volume of 8 ml/kg, and positive end-expiratory pressure
ranged from 7 to 9 cm H2O. Respiratory rate was ≈18 beats per minute.
A 7 French pulmonary artery catheter (Swan–Ganz; Edwards Lifesciences World Trade Co.
Ltd, Irvine, CA, USA) was inserted through the right external jugular vein using an 8 French
introducer sheath (Medtronic, Minneapolis, MN, USA) for continuous pulmonary artery pressure
monitoring, MS injection and blood samples extraction. The Swan-Ganz catheter tip was located
in the main pulmonary artery. Additionally, ECG and pulse-oximetry were monitored during
the entire experiment.
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5.3.2 PET image acquisition
PET/CT images were acquired using a Gemini TF-64 scanner (Philips Healthcare, Best, The
Netherlands). Animals were placed supine and three 68Ga-DOTA-PET scans were obtained
under similar physiological conditions for each animal with gaps of 30 minutes between consec-
utive scans to allow for physical and biological decay. However, some remaining activity was
accumulated in subsequent scans as is schematically shown in Fig. 5.1. In order to measure
the background activity, a 60 second frame was acquired prior to the radiotracer injection and
included in the kinetic modeling. No further background corrections were required. Each scan
consisted in a low dose CT scan (120 kV, 80 mA) followed by a 10 min list mode PET acquisition
in a single bed position covering 18 cm of axial extension. The radiotracer prepared in 7 ml vol-
ume was infused with a pump at a rate of 0.2 ml/s (35 seconds injection) through the marginal
ear vein (66 ± 33 MBq). PET scans were started 1 min prior to the radiotracer injection. Each
PET acquisition was reconstructed in 41 consecutive frames (1 × 60 s, 24 × 5 s, 6 × 10 s, 3 ×
20 s, 4 × 30 s and 3 × 60 s) and 3D-RAMLA reconstruction algorithm was used in all cases
producing images with a voxel size of 4 × 4 × 4 mm3.
Figure 5.1: Timeline of the protocol followed for each animal. Colored boxes indicate the duration and the time
at which every action was being performed. The timeline is superimposed on a schematic AIF (dashed line), and
radiotracer accumulation can be noticed at the beginning of the second (t = 30 min) and third (t = 60 min) scans.
Each radiotracer injection was performed simultaneously to the injection of 15-µm fluorescent
MS (FluoroSpheres R©, Molecular probes, Eugene, OR, USA). Each MS injection consisted of 5
× 105 beads diluted into 10 ml of saline containing 0.01% Tween 80. The MS were manually
injected over ∼60 s directly into the right atrium via the Swan-Ganz catheter. Different MS
colors were used on each of the three injections provided to the same animal including green (λ
= 450/480 nm), yellow (λ = 515/534 nm), and red-orange (λ = 565/580 nm). Immediately before
MS dilution, the vial was vigorously vortexed for 15 s, sonicated for 4 min and vortexed again
for additional 15 s. Reference blood samples were drawn from the pulmonary artery through
the Swan-Ganz into a heparinized syringe at a rate of 5 ml/min (for 3 min) with an automated
syringe pump (Harvard PHD 22/2000 Advance Syringe Pump, Harvard Apparatus), starting 1
min before MS injection. Additionally, another blood sample was taken from the pulmonary
artery for hematocrit measurement.
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5.3.3 PET data analysis
PBF derived from MRI typically uses a single compartment model as the acquisition is obtained
during one breath-hold and extravasation can be neglected. However, our PET data is acquired
in free-breathing during several minutes and extravasation becomes a relevant factor. Therefore,
the use of two-tissue compartments was considered to account for the capillary bed and the
interstitial volume. In this way, parametric PBF images (PBFPET) were generated voxel-wise
applying a two-compartment exchange model (2CXM) [200] over the dynamic PET images. This
model considers the plasma volume of the lung capillary bed as the central compartment which
occupies a fractional volume vp, with a tracer concentration Cp(t), and the interstitial volume as
the peripheral compartment which occupies a fractional volume ve with a tracer concentration
Ce(t). The exchange rate between the two compartments is described by the permeability-surface
product (PS). Thus, tracer concentrations over time in both compartments are explained by their
mass balance equations (see Eqs. 5.1 and 5.2).
vp
dCp(t)
dt
= FpCa (t) − FpCp (t) + PSCe (t) − PSCp(t) (5.1)
ve
dCe(t)
dt
= PSCp (t) − PSCe(t) , (5.2)
where Ca(t) is the radiotracer concentration in the arterial plasma (i.e., the AIF) and Fp is the
pulmonary plasma flow. Tissue tracer concentration is the sum of concentrations in plasma and
interstitial space weighted by each particular fractional volume (see Eq. 5.3).
Ct (t) = vpCp (t) + veCe(t) . (5.3)
This set of differential equations can be solved as the convolution of Ca(t) with the impulse
response function (IRF):
Ct (t) = Ca (t − δ) ⊗ IRF (t) (5.4)
IRF (t) = ve + vp
vevp
PS · Fp
(
e−tE− − e−tE+
E+ − E−
)
+ Fp
(
E+e−tE+ − E−e−tE−
E+ + E−
)
, (5.5)
where E+ and E− are positive, non-zero quantities defined as
E± =
1
2
©­«
veFp + vePS + vpPS
vevp
±
√(
veFp + vePS + vpPS
vevp
)2
− 4PSFp
vevp
ª®¬ . (5.6)
Therefore, the implemented 2CXM model contains four fit parameters including vp, ve, Fp
and PS. The most relevant parameter for our purpose is the pulmonary plasma flow (Fp), which
can be converted into the pulmonary blood flow (PBF) via the hematocrit value of the lung
tissue:
PBF =
Fp
1 − HT , (5.7)
where HT represents the hematocrit value. In Eq. 5.7, PBF is obtained in units of volume of
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blood per time and volume of tissue (ml·min−1·ml−1) but, in order to compare with the (MS)
results, PBF must be expressed as volume of blood per time and mass of tissue (ml·min−1·g−1).
To account for this, PBF value was corrected by density and blood fraction. The CT values
were used to obtain lung density values (tissue + blood) [89] assuming a linear behavior between
CT value and tissue density in the range from air (-1024 HU, ρ ≈ 0 g·cm−3) to water (0 HU,
ρ = 1 g·cm−3) [36, 187]. The blood contribution was subtracted using the plasma fractional
volume (vp) obtained in the minimization process (see Eqs. 5.8 and 5.9).
PBF
[
ml ·min−1 · g−1] = PBF [ml ·min−1 ·ml−1]
ρlung − vp1−HT ρblood
, (5.8)
where a blood density (ρblood) of 1 g·cm−3 was used and lung density (ρlung) was computed in
a pixel by pixel basis as
ρlung =
1024 + CTi
1024
, (5.9)
where CTi is the CT value (HU) measured at voxel i.
It can be noticed that the AIF employed for the analysis is delayed δ seconds with respect
to the voxel TACs, as it was derived from the right ventricle and there is some delay until it
reaches the lung capillaries. A delay of 2 seconds was used since a transit time of 4 seconds was
observed from the right to the left ventricle. The same value was used in other studies with
15O-labeled water [176]. The delayed AIFs were interpolated to match PET measurement times.
The radiotracer flows from the pulmonary arteries to the veins through the capillary bed and
extravasates to the interstitial space. Therefore, the radiotracer concentration can be expressed
in terms of the plasma concentration in the arterial input, the plasma flow, the plasma volume,
the permeability–surface area product, and the interstitial volume.
Importantly, this time the AIF was not obtained from the LV but from the RV. This is
because the blood that perfuses the lungs is supplied by the pulmonary artery, which carries the
blood from the RV to the lungs. Consequently, the arterial input function (AIF) (see Fig. 5.2A)
was obtained from the mean voxel value at each time point within a small volume of interest
(VOI) drawn inside the right ventricle and was corrected by the pulmonary artery hematocrit to
obtain the radiotracer concentration in arterial plasma.
The non-linear fit of the TAC of each voxel was performed by a minimization of the sum
of squares using a modified Levenberg-Marquardt method for bound constraints with a Python-
coded customized software including scipy and numpy libraries. Fig. 5.2B shows an illustrative
fit to the average TAC of a large region within the lung.
On each animal, right and left lungs were segmented separately, and each lung was divided
into three transversal regions (apical, medial and basal) with the same axial extension to facilitate
regional comparison with the MS measurements (see Fig. 5.3). The PBF for each region was
computed as the average PBF of those voxels with CT values between -925 and 0 HU in order
to reject large vessels and airways. A morphological erosion image filtering with 4 mm size was
performed over the VOI of the lung to avoid spillover contribution from heart or liver.
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Figure 5.2: A: An example of TACs obtained for a large region of the lung (dots) and right ventricle (solid line).
B: TAC from the lung (dots) and fit to a two-compartment exchange model (solid line).
Figure 5.3: Coronal view of an in vivo CT image indicating the segmentation of the lungs performed for the
regional validation against MS. Regions 1-2 (red), 3-4 (blue) and 5-6 (green) correspond to the basal, medial and
apical zones of the right-left lungs respectively.
5.3.4 Microspheres analysis
The MS analysis was based on the same protocol followed in Chapter 3 [193] with minor modifi-
cations. In brief, the pigs were sacrificed the day after PET scans were performed and the lungs
were extracted. The lungs were expanded to recover anatomic references and make easier the
comparison between zones in PET and excised lungs. To this purpose, the pig was sedated as
previously described and euthanized by an intravenous overdose of pentobarbital in supine posi-
tion while intubated. The animal was mechanically ventilated with similar conditions than those
for the in vivo experiments. The trachea was clamped at the end of inspiration and the lungs
were extracted. An ex vivo CT scan of them was performed to guide the registration between
in vivo images and post-mortem validation MS analysis. Afterwards, the lungs were wrapped
in plastic film and frozen at -20◦C. Finally, right and left lungs were separated and individually
divided into transversal slices (1–2 cm thickness) (see Fig. 5.4).
For tissue processing, each lung piece was weighted and immersed in a KOH 4N solution (5
ml per gram of tissue). At the same time, each reference blood sample withdrawn during the
experiment was taken to 60 ml with 2% Tween 80, followed by addition of 14 ml of KOH 16N.
All samples were incubated at 37◦C under vigorous shaking for 24–48 hours. This incubation
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Figure 5.4: Process followed parting from frozen lungs to obtain pieces that were further digested. Both left and
right lungs were sliced in three regions: 1-2 (basal), 3-4 (medial) and 5-6 (apical) that would spatially correlate to
ROIs in PET analysis, as those drawn in Fig. 5.3.
time (24–48 hours) is shorter than that needed to digest cardiac tissue samples (48–72 hours) as
lung tissue is softer.
After complete tissue digestion, samples were individually filtered with negative pressure
filtration. A different filter (Nylon Net Filter 10 µm, Merck Millipore, Burlington, MA, USA)
was used for each sample. Each digested sample was poured onto the filter, and the containing
tube was rinsed with ∼20 ml of 2% Tween 80 to ensure the collection of all the MS. Next, the filter
was rinsed with ∼10 ml of buffer rinse solution (KH2PO4/K2HPO4 at pH = 7.2) to neutralize
the pH of the nylon filter.
Each filter was immersed in 10 ml of cellosolve acetate (2-ethoxyethyl acetate 98%, Sigma,
Saint Louis, MO, USA) and stored in the dark for 2–3 h, until the complete dissolution of the MS
polystyrene cover. The fluorescence of the resultant solution was measured with a fluorescence
spectrometer (PerkinElmer LS 55, Waltham, MA, USA) at the emission/excitation wavelengths
of 450/480 nm, 515/534 nm and 565/580 nm for the green, yellow and red-orange MS respectively.
Both emission and excitation slits were set at 5.0 nm for every reading. Finally, the fluorescence
intensities of each sample were used to compute the PBF (PBFMS) following the standard MS
reference technique [58]. Each sample was assigned to one of the lung six regions segmented in
the parametric PBFPET images (see Fig. 5.3). The PBF of each region was calculated adding
the fluorescent and weight values of the samples assigned to it.
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5.3.5 Statistical analysis
PBFPET and PBFMS values were directly compared by regression analysis. F test was used to
study the null hypothesis of the y-intercept of the linear fits being zero. Also, Pearson correlation
coefficient was estimated, and Bland-Altman plot was used to assess agreement between PBFPET
and PBFMS results. All the measurements were statistically considered as independent events
as the MS results showed high variability for measurements repeated on the same animal and a
wide range of PBF values was covered with all the animals. As usual, p < 0.05 was considered
statistically significant.
5.4 Results
Physiological variables were stable during the scan. Heart rate was 100 ± 16 beats per minute
(bpm), mean pulmonary artery pressure was always under 25 mmHg, and oxygen saturation was
over 98%. A hematocrit value of 0.3, similar to the value used in other perfusion studies with
varied techniques, was used for all analyses.
5.4.1 Parametric PBF maps
Fig. 5.5 shows examples of PBFPET images at different axial slices, demonstrating the capability
of this technique to produce 3D regional PBF. The images are fused with their corresponding
CT slices for visualization purposes only. PBF values are displayed only for those voxels with
CT values in the range from -925 to 0 HU. As expected, the dorsal regions show higher PBF
values compared to ventral regions as a consequence of the supine position of the animal during
the imaging sessions [177].
5.4.2 Comparison PBFPET versus PBFMS
Bland-Altman plot (Fig. 5.6) shows the evaluation of the agreement between PBFPET and
PBFMS including 57 samples. Measured bias was −1.86 ml·min−1·g−1 and limits of agreement
(LOA) ranged from −11.79 to 8.08 ml·min−1·g−1. The slightly negative trend (slope = −0.14)
found in linear fit of these data (PBFPET-PBFMS differences against PBFPET-PBFMS average)
was not significant (p = 0.16), so no correction was applied to the data, and agreement between
PBF measurement with PET and gold standard MS could be concluded.
The MS measurement corresponding to the blood sample of the third scan in pig #4 showed
atypical and extremely low fluorescence values compared to background level. As this can increase
the probability of measurement errors, the 6 points corresponding to this scan were excluded from
the analysis. Results of the agreement without the data exclusion lead to a bias and LOA of
−3.51 ml·min−1·g−1 and from −16.30 ml·min−1·g−1 to 9.27 ml·min−1·g−1 respectively.
Evaluation of the correlation between PBFPET and PBFMS including 57 samples is shown in
Fig. 5.7. The null hypothesis of a y-intercept = 0 was rejected by the F test, and the PBFPET-
PBFMS pair of values were fitted to a line with non-zero y-intercept. The methods showed a
good and significant correlation (r = 0.77, p < 0.0001) when perfusion across all the measured
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Figure 5.5: Fused transverse parametric PBFPET and CT images at four different axial locations of the same
animal.
Figure 5.6: Assessment of agreement between PBFPET and PBFMS. Apical (green), medial (blue) and basal
(red) regions are shown. The solid lines represent the mean bias (−1.86 ml·min−1·g−1) and the dashed lines
represent the 95% confidence interval (mean ± 1.96 SD).
regions of the lung were evaluated, and was maintained when the evaluation was done by lung
zones: r = 0.83 (p < 0.0001), r = 0.72 (p < 0.0001) and r = 0.82 (p < 0.0001) for apical, medial
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and basal zones respectively. The goodness of fit worsens (r = 0.66, p < 0.0001 for the entire
lung; r = 0.76, p < 0.0001 for the apical; r = 0.63, p < 0.0001 for the medial; and r = 0.74,
p < 0.0001 for the basal zone) when the correlation is performed without the exclusion of the 6
points mentioned before, which is in line with the possibility of measurement errors.
Figure 5.7: Correlation between PBFPET and PBFMS. Apical (green), medial (blue) and basal (red) regions are
shown. The dashed line represents regression line to all the points (r = 0.77, p < 0.0001).
5.5 Discussion
In this chapter, the use of 68Ga-DOTA-PET for the in vivo quantitative determination of re-
gional PBF is proposed. The methodology required to perform these studies was implemented
and tested in healthy pigs. Finally, the in vivo measurements of regional PBF were validated
using fluorescent MS. This is a reliable and easily implementable alternative to dynamic contrast
enhanced MRI, where quantification is very challenging due to the non-lineal dependence of sig-
nal intensity with the Gadolinium-based contrast agent concentration [154]. This is even more
important due to the fact that these agents, either linear or macrocyclic, are under investiga-
tion for multiple results demonstrating their potential accumulation in various tissues regardless
of renal function [136]. Our alternative has a simpler implementation and provides quantitative
measures of the regional blood flow compared to recent approaches using dual energy CT imaging
[64, 99]. Compared to other PET based alternatives such as H215O [191] or dissolved 13N2 [151]
that need an on-site cyclotron, our solution could be potentially more widely available due to
the introduction of gallium generators in the field and the approval of different gallium-chelated
agents for human use. Our local estimation cost is 100 euros per study including proportional use
of the generator, reactive agents and lab technicians. Compared to other nuclear medicine tech-
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niques such as 99mTc macroaggregated albumin [17], which also reflects true perfusion, SPECT
shows lower spatial resolution and longer acquisition times.
We have demonstrated the capability of the proposed technique to obtain in vivo 3D regional
PBF. Comparative PBFPET and PBFMS values in dorsal and ventral regions were not obtained
due to the difficulty to achieve a good in vivo and ex vivo registration.
The results of this study show potential for 68Ga-DOTA radiotracer in clinical practice for
measuring PBF. Pulmonary perfusion is an important variable for understanding lung function,
especially when it can be described regionally. Such relevance has allowed the advances in
imaging techniques for lung perfusion and perfusion distribution to become an attractive tool for
diagnosis and outcomes prediction and evaluation. For example, differences in perfusion patterns
measured by dual CT [78, 140] are being proposed for diagnosis of PH and even to differentiate
pulmonary arterial hypertension (PAH) from chronic thromboembolic pulmonary hypertension
(CTEPH) [73]. Recently Lau et al. [115] showed using SPECT/CT that pulmonary pre-capillary
hypertension showed a redistribution of flow changing the gravidity influence, which appears as
a potential tool for disease severity evaluation. Not only PH but also other lung diseases such as
COPD have shown alterations in perfusion, which in this disease is related to impaired pulmonary
function indexes, appearing also promising for severity evaluation.
The good correlation existing between PBFPET and PBFMS (see Fig. 5.7) shows high
potential for the determination of quantitative regional PBF in vivo and non-invasively using
68Ga-DOTA-PET. Noteworthy, the r-value and slope obtained in this study are comparable to
those calculated by Schuster et al. [192] (r = 0.77, slope = 0.92) and Richard et al. [176] (r = 0.79,
slope = 0.79) using PET and 15O-labeled water. Unfortunately, there is no PBF obtained by CT
to compare with our results [64, 99].
The obtained PBFPET values display a small underestimation compared to PBFMS repre-
senting only 10% of the maximum PBF obtained. The underestimation could be explained by the
difference between the hematocrit of the blood contained in an arteriole or venule of the capillary
bed (tube hematocrit HT ) relative to the hematocrit of blood entering or leaving it (discharge
hematocrit HD). This difference can be explained by the Fåhræus effect [57] and results in a
decreasing hematocrit as blood traverses the microvasculature. In our work we assumed that HT
equals to HD, but a proper correction would result in an increment of PBF values as shown in
Eq. 5.10. Pries et al. [166] reported a HT/HD ratio of 0.65 for HD = 0.3 at 10 µm diameter
capillaries. This correction would increase PBF by 15%.
PBF ′ = PBF
1 − HT
1 − HD . (5.10)
It also has to be noticed that Pearson correlation values between PBFMS and PBFPET is
limited by the registration inaccuracy between the regions of the in vivo PET scan and the ex
vivo MS measurements. A possible improvement for this comparison would be the use of 68Ga-
labeled MS that could be quantified by a PET scan keeping the animal in the same position as
in the 68Ga-DOTA scan.
60 Chapter 5: Pulmonary blood flow assessment using 68Ga-DOTA-PET
Another source of error can be the delay between the AIF derived from the right ventricle and
the arrival of the radiotracer to every tissue voxel [86]. Imprecise delays can produce deviations up
to 40% [176]. In this study, we assumed a constant delay of 2 seconds, but further improvements
can be performed in order to include this delay time as a free parameter in the non-linear fit.
Finally, the AIF was not corrected by partial volume effect that can have quantitative effects on
the results [95].
Although the animals were studied under basal conditions, a wide variability of heart rate
and PBF values was obtained. This was probably due to the fact that the animals were mechan-
ically ventilated in pressure support ventilation mode, which required adjusting the anesthesia
between consecutive scans in order to maintain the animal stable under mechanical ventilation.
However, this effect was transient, and all animals remained stable across each acquisition. In
the other hand, such variations allowed us to explore a wider range of perfusion values.
5.5.1 Study limitations
Despite the promising results, this study was performed just in normal animals. However, the
main possible applications of this new method are related with the study of diseased states.
As pulmonary flow is related with important physiologic processes such as gas exchange and
also right ventricle afterload, the ability to track it in a quantitative and reliable way in usual
clinical practice could potentially improve disease understanding and patient care. Although
non-disease states were studied, PBF was evaluated in a wide range of values. Also, to the best
of our knowledge both the tracer behavior itself and the implemented analysis should remain
valid in pathologic conditions. Based on this, we believe our PBFPET using 68Ga-DOTA appears
as a potential quantitative diagnostic imaging biomarker of endothelial dysfunction in important
lung diseases. This, however, still needs to be proven.
Another limitation of our study is the small number of animals (n = 4). However, 57
independent measures were used for the agreement and correlation studies corresponding to the
three scans performed to each animal and the three transversal regions of each lung. With this,
we were able to find acceptable agreement and good and significant correlation between PBFPET
and the gold standard measurements. Using a larger number of animals could have improved our
results through a decrease in measured variability but it is probably unjustified by the current
needs of reducing the number of experimental animals.
Finally, as most of the current implemented methods, 68Ga-DOTA PBFPET can offer a
regional perfusion estimation, which represents a mean value across the entire respiratory cycle.
However, mainly due to the volume and pressure changes within the lungs during the respiration
it is reasonable to expect that the local perfusion be different according to the respiratory phase.
In this way dynamic evaluation of lung perfusion in normal and diseased status could appear as a
promissory research field. This aspect could be studied with the proposed technique by applying
respiratory synchronization to measured PET data or performing data acquisition during apnea
or at the end-of-expiration. However, this was out of the scope of this study.
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5.6 Conclusions
In this study, the determination of regional PBF using 68Ga-DOTA-PET imaging was proposed,
implemented and validated. Assessment of PBF with this technique allows combining the high
quantitative accuracy of PET imaging with the much easier access to 68Ge/68Ga generators
compared to existing techniques using H215O that require an on-site cyclotron. In this way
68Ga-DOTA-PET appears as a potential method for measuring PBF in clinical settings with an
extended use, and widens the range of applications of 68Ga-DOTA-PET imaging.
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6
MULTI-TRACER PET USING BLOOD SAMPLING SPECTROSCOPY
6.1 Introduction
The work shown in the previous chapters has proposed the use of 68Ga-DOTA as a new PET
radiotracer, which would allow to expand the use of PET for the clinical evaluation of MBF,
viability and PBF [11, 12, 108, 213, 214]. Thanks to its ease of production and low cost, 68Ga-
DOTA may join the club of the most used radiotracers in clinical cardiac studies (18FDG, H215O,
13NH3 and 82Rb). Noteworthy, 68Ga-DOTA possesses a special feature that the aforementioned
do not, and it has not been exploited yet; 68Ga emits an additional high-energy gamma ray apart
from the β+ decays, and this fact may be useful as we will see next.
It has been stated that PET is a diagnostic molecular imaging technique that allows in vivo
monitoring of metabolic processes within the body based on the biodistribution of a radiotracer
that is administered to the patient. There is a wide variety of available radiotracers that provide
access to different biological aspects such as glucose metabolism, cell proliferation, hypoxia or
blood flow, and among the different radiotracers available, each one shows strengths and limita-
tions for a particular clinical application [224]. Based on this knowledge, the nuclear medicine
physician selects the tracer that will provide the most specific and reliable information for the
patient under study. However, in many clinical cases, diagnostic accuracy can be increased con-
siderably if complementary information is obtained from different tracers. In fact, an example of
diagnosis using multiple tracers is found in CAD, which includes evaluation of myocardial blood
flow (MBF) using tracers as 13NH3, H215O or 82Rb, and assessment of myocardial metabolism
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and viability using 18FDG. In this way, a better understanding of the pathophysiology of CAD
is obtained [72].
Conventional PET imaging has usually been limited to a single tracer per scan. Therefore,
in order to perform PET examinations with multiple tracers on the same patient, different scans
should be performed sequentially if the half-life of one tracer is short enough (i.e., tracers based
on 13N, 15O or 82Rb) to allow fast clearance of the tracer before the next tracer is administered.
Otherwise, scans can be performed in different days. These procedures lead to extended scan
time and to increased cost and complexity of patient management. Those limitations can be
diminished by performing PET imaging on patients that have been administered with multiple
radiotracers. However, multi-tracer PET imaging is still a challenging approach as annihilation
photon pairs emitted from either tracer are indistinguishable. Therefore, some extra information
is needed to disentangle the signal coming from each tracer.
Two main strategies have been proposed so far in order to enable the possibility of perform-
ing PET scans with multiple tracers simultaneously. The first approach uses dynamic imaging
with staggered injections. In this case, a multiple-tracer compartment model is used applying
constraints on the kinetic behavior in order to separate each tracer contribution from the multi-
tracer PET signal [96, 104, 216]. In a second approach, at least one of the injected tracers must
be labeled with a radioisotope that emits a prompt gamma in addition to the positron, which
can be detected in coincidence with the annihilation photons [5, 37]. With this additional infor-
mation, the signal coming from both tracers can be isolated by energy discrimination within the
PET scanner. However, a high branching ratio of the prompt gamma is required in these cases,
reducing the list of tracer candidates to 124I or those with similar prompt gamma branching
ratio.
6.2 Aim of the chapter
In this chapter, we propose a new technique for multi-tracer PET imaging that uses dynamic
imaging and multi-tracer compartment modelling, including an explicitly derived arterial input
function (AIF) for each tracer. In order to end up with a separate AIF for each radiotracer, blood
samples were collected during the PET/CT acquisitions and further analyzed by gamma spec-
troscopy. Once separate AIFs were obtained, multi-tracer compartment modelling was applied to
determine the kinetic parameters associated to each tracer. This methodology was implemented
and validated in pigs by combination of 68Ga-DOTA and 18FDG.
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6.3 Methods
6.3.1 Study design and experiment overview
In the first place, in vitro studies were performed as a proof of concept of our proposed method-
ology. Samples containing unknown mixtures of two isotopes (18F and 68Ga) were analyzed by
means of gamma spectroscopy. Several calibration procedures were accomplished in order to
obtain the individual contribution of each tracer. For in vivo studies, 18FDG and 68Ga-DOTA
tracers were administered to healthy pigs and dynamic PET scans were performed. Manual
blood samples were collected throughout the PET scan and analyzed by gamma spectroscopy
to obtain a separate AIF for each tracer. A multi-tracer compartment model was applied on
the dynamic PET imaging using those explicitly separated AIFs. Finally, the model was used
to determine the uptake of each tracer at the end of the PET scan on each segment of the my-
ocardium and the results were compared with those obtained ex vivo directly from myocardial
tissue. For that purpose, animals were sacrificed, and the heart was excised in segments that
were further analyzed to determine the individual uptake of each tracer ex vivo. A schematic
drawing of the experimental protocol is shown in Fig. 6.1.
6.3.2 In vitro tracer separation by gamma spectroscopy
We analyzed different combinations of two tracers, one based on a pure positron emitter (18F) and
the other one based on a non-pure positron emitter (68Ga). While 18F only emits annihilation
photons of 511 keV, 68Ga emits additional photons, but only those emitted at 1.077 MeV have a
significant contribution (3.22%). Therefore, a sample containing an unknown combination of both
isotopes could be analyzed by means of gamma spectroscopy. To determine the concentration
of each tracer in a sample, a methodology was developed using a well counter (Wallac 1470
Perkin Elmer, Waltham, MA, USA) configured to record events during 1 minute at different
energy windows simultaneously, one of them covering the entire energy spectrum (200–2000
keV, hereafter named as W200−2000) and the other one covering only high energy emissions (900–
2000 keV, hereafter named as W900−2000). Dead time correction and background subtraction
were implemented but not decay correction due to the unknown isotope combination. The
amount of 68Ga and 18F contained in the sample was derived using the quotient (QS) between
events recorded at W200−2000 and W900−2000 energy windows as explained below. The relationship
between QS and the relative activity of 68Ga (RGa) and 18F (RF) in a sample (i.e., the individual
fractional contribution of 68Ga and 18F to the total activity of the sample) was calibrated using a
set of 68Ga/18F mixtures. Seven 1 ml samples were prepared containing 68Ga:18F activity ratios
of 1:0, 9:1, 4:1, 3:2, 2:3, 1:4 and 0:1. These samples were analyzed in the well counter and the
QS values were represented against the known relative activities obtaining a linear relationship
(see Fig. 6.2).
Decay correction was applied to recorded values. Since in the subsequent animal studies
blood samples may be collected with different sample volumes (VS), a calibration had to be
performed to account for variations in detection efficiency of gamma rays with different energy
and different geometrical distribution. For that purpose, Q values were recorded using pure 18F
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Figure 6.1: Schematic drawing of the study design. A: Firstly, our proposed tracer separation methodology based
on gamma spectroscopy was evaluated in vitro as a proof of concept. Samples containing a known combination
of two radioisotopes (18F and 68Ga) were analyzed and the activity concentrations of each separate radioisotope
were obtained. B: Afterwards, this methodology was implemented in vivo. To do so, three pigs underwent 45-
min cardiac dynamic PET/CT scans in which 68Ga-DOTA and 18FDG were injected with a 5-min time gap.
After PET/CT examination, the animals were sacrificed and their hearts were excised, divided into segments and
analyzed to obtain the activity concentration of 18FDG and 68Ga-DOTA inside each segment. These results were
compared against those obtained in vivo by parallel multi-tracer pharmacokinetic analysis on the same regions of
interest (ROIs) of their hearts. Explicitly separated AIFs needed for the pharmacokinetic analysis were obtained
from the pigs with our proposed method by gamma spectroscopy of a set of blood samples withdrawn during the
scan.
(QF (V)) and 68Ga (QGa(V)) samples (∼20 kBq each) with volumes ranging from 50 to 2000 µl
(see Fig. 6.3). For known QF (V) and QGa(V) within a sufficiently wide volume range, RGa and
RF can be obtained for a sample with known volume (VS) by solving the following equations:
Qs(VS) = RGa · QGa(VS) + RF · QF (VS) (6.1)
RGa + RF = 1 . (6.2)
Afterwards, the absolute activity concentrations of each tracer (i.e., AF and AGa) can be obtained
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Figure 6.2: Calibration of QS values from a set of 1 ml samples with mixed 68Ga and 18F at different activity
ratios. The linear fit (dashed line) shows an excellent linear correlation (r2 = 0.9992) between both datasets.
for a sample of known volume VS as follows:
AGa
[
kBq ·ml−1] = Atot · RGa
VS
, (6.3)
where Atot is the total activity of the sample and can be derived from the next equation:
W200−2000 = WF +WGa = Atot (εFRF + εGaRGa) , (6.4)
where WF and WGa are the events recorded for each isotope, and εF and εGa are volume-
dependent calibration factors obtained from pure 18F and 68Ga samples respectively (see Fig.
6.4). Finally, before the kinetic model could be individually applied for each tracer, AF and AGa
were converted to β+decays·s−1·ml−1 multiplying by their respective branching ratios in order to
match the units obtained from the PET images.
Following this procedure, explicitly separated AIFs can be obtained from a multi-tracer PET
scan by analyzing a set of blood samples withdrawn from the subject throughout the study and
obtaining AF and AGa for each timepoint. The feasibility of this methodology was investigated
in animal studies as described below.
6.3.3 Animal protocol
This in vivo study was also conducted according to the guidelines of the current European
Directive and Spanish legislation and approved by the regional ethical committee for animal
experimentation. Three healthy female Large White pigs (mean weight = 45 ± 4 kg) were anes-
thetized by intramuscular injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam
(0.5 mg/kg), and maintained by continuous intravenous infusion of ketamine (2 mg·kg−1·h−1),
xylazine (0.2 mg·kg−1·h−1), and midazolam (0.2 mg·kg−1·h−1). Oxygen saturation levels via pulse
oximetry, and ECG signal were monitored throughout the study. Coccygeal artery of the animal
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Figure 6.3: Variation of QS values measured with the well counter for pure 18F (red squares) and 68Ga (blue
circles) with different sample volumes (VS). Results were fitted to a straight line and a sum of two exponential
functions respectively in order to obtain the QS values for different volumes.
was cannulated and connected to a peristaltic pump placed as close as possible to minimize blood
dispersion inside the tubing.
6.3.4 PET/CT image acquisition
PET/CT images were acquired using a Gemini TF-64 scanner (Philips Healthcare, Best, The
Netherlands). Each imaging study consisted of a low dose CT scan (120 kV, 80 mA) followed by
a dynamic 45-min list mode PET acquisition in a single bed position covering the entire heart.
18FDG (155 ± 12 MBq) and 68Ga-DOTA (142 ± 33 MBq) were injected 1 and 6 minutes after
PET scan was started respectively. Both radiotracers were prepared in 6 ml and infused at a rate
of 1.0 ml/s through a marginal ear vein, followed by a 6 ml saline flush at the same rate. Arterial
blood was withdrawn during the PET scan through a 1.6-mm internal diameter peristaltic pump
tubing (TYGON-XL6, Saint-Gobain, Courbevoie, France) at 5 ml/min for the first 7 minutes,
and then at 2 ml/min for the rest of the scan. Blood collection from the coccygeal artery started
immediately after the first radiotracer injection and continued during the whole study. During
the first 12 minutes, blood was collected into sample tubes according to the following scheme: 20
× 5 s, 8 × 10 s, 6 × 20 s, 24 × 5 s, 6 × 10 s, 6 × 20 s, 4 × 30 s. After that, 11 more samples were
collected for 1 minute with 2 min gaps among samples. PET images were reconstructed with
a voxel size of 4 × 4 × 4 mm3 using a 3D-RAMLA reconstruction algorithm in 85 consecutive
frames (1 × 60 s, 25 × 5 s, 8 × 10 s, 4 × 20 s, 24 × 5 s, 3 × 10 s, 5 × 20 s, 5 × 60 s, 4 × 120
s, 4 × 180 s and 1 × 300 s). Corrections for dead time, scatter and random coincidences were
applied as implemented on the scanner. Decay and branching ratio corrections were not applied
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Figure 6.4: A: Calibration profiles obtained in the well counter for 300-µl pure 18F (red squares) and 68Ga (blue
circles) samples with different activity values using the full energy window (W200−2000). Each dataset was fitted to
a straight line with y-intercept forced to be 0 obtaining the calibration factors εF = 0.335 cps/Bq and εGa = 0.371
cps/Bq at this volume. B: Variation of calibration factors with the sample volume for 18F (εF ) and 68Ga (εGa).
as the amount of 68Ga and 18F on each voxel was unknown and their values differ (t1/2(68Ga) =
67.77 min and t1/2(18F) = 109.77 min, BrGa = 0.891 and BrF = 0.967). Therefore, reconstructed
images were expressed as β+decays·s−1·ml−1.
6.3.5 Separate AIF derivation from blood sample gamma spectroscopy
After each PET/CT examination, the vials containing the collected blood samples were cen-
trifuged briefly to provide a reproducible geometrical distribution of the blood before performing
the measurements in the well counter. The volume for each blood sample was determined as
the weight difference between empty and filled vial and considering a blood density of 1.03 g/ml
[179]. Then, the individual activity concentration of 18FDG and 68Ga-DOTA (AF and AGa) for
each blood sample was calculated using Eqs. (6.1)–(6.4). Consequently, the AIFs obtained from
blood samples for each tracer (AIFBS,F and AIFBS,Ga) were derived as time series of this values.
Delay and dispersion corrections were applied to AIFBS,F and AIFBS,Ga using the image-
derived AIF (AIFID) as this one lacks from delay and dispersion. AIFID was obtained from an
8-mm diameter cylindrical volume of interest (VOI) drawn in the descending thoracic aorta over 5
consecutive slices of the dynamic PET images. Spill-out from the AIF was corrected normalizing
to the activity measured inside a 10 mm-diameter spherical VOI placed inside the left ventricle
averaged over the latest frames. Delay was corrected by maximizing the cross-correlation between
AIFBS (sum of AIFBS,F and AIFBS,Ga) and AIFID. In order to obtain dispersion-free AIFs, we
assumed that at the moment of second tracer injection (at time t2), the blood concentration of
the first tracer was changing slowly and therefore did not suffer from dispersion. Thus, dispersion
before t2 was corrected by using the AIFID as there was only contribution from the first tracer.
After t2, we assumed that AIFID,F and AIFBS,F were equal and dispersion-free AIF for the second
tracer could be obtained by direct subtraction of AIFID and AIFBS,F . Thus, dispersion-free AIFF
and AIFGa used for pharmacokinetic analysis was derived as follows:
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AIFGa =

0 , t < t2
AIFID − AIFBS,F , t ≥ t2
AIFF =

AIFID , t < t2
AIFBS,F , t ≥ t2
, (6.5)
6.3.6 Kinetic modelling and image analysis
Parallel multi-tracer compartment modelling [96, 104, 107, 113], was applied to the recorded PET
data where each tracer’s kinetic behavior was introduced according to its pharmacokinetic model
and to its individual AIF. 68Ga-DOTA diffuses bidirectionally between the intravascular and the
interstitial space suggesting the use of a single-tissue compartment model (1TCM) [11, 214] (see
Fig. 6.5A). On the other hand, 18FDG is explained with an irreversible two-tissue compartment
kinetic model (2TCM). (Fig. 6.5B). Therefore, the total tracer concentration measured in the
tissue (Ctis(t)) could be expressed as the sum contribution from both tracers:
Ctis(t) =
∑
i=Ga,F
Ctis,i(t) + PVE(t) =
∑
i=Ga,F
IRFi
({k j ,i}, t) ⊗ Cp,i(t) + PVE(t) , (6.6)
where IRFi
({k j ,i}, t) is the impulse response function for tracer i, {k j ,i} are the kinetic parame-
ters, Cp,i(t) is the activity concentration in plasma for tracer i and PVE(t) denotes the spill-over
of radioactivity coming from LV and RV into myocardium. These IRFs can be described by the
pharmacokinetic model that follows each tracer:
IRFGa
(
K1,Ga, k2,Ga, t
)
= K1,Ga · e−k2,Ga t (6.7)
IRFF
(
K1,F, k2,F, k3,F, t
)
= K1,F
(
k2,F
k2,F + k3,F
e−(k2,F+k3,F )t +
k3,F
k2,F + k3,F
)
. (6.8)
In order to obtain the free 68Ga-DOTA concentration in plasma Cp,Ga(t), hematocrit (H)
and free metabolite fraction (F) must be used. These values have been previously determined
[214]. On the other hand, 18FDG concentration in plasma for myocardial tissue has already been
described [161]. Therefore, the relation between AIF(t) and Cp(t) for both tracers can be then
described as:
Cp,Ga(t) = F
1 − H · AIFGa(t) (6.9)
Cp,F (t) = (0.8 + 0.0012t) · AIFF (t) (6.10)
PVE contribution was not split for each tracer as it can be considered a function of the total
blood activity concentration. It can be further decomposed in different components as:
PVE(t) = VAP · CAP(t) + VLV · CLV (t) + VRV · CRV (t) , (6.11)
where VLV , VRV and VAP represent the spill-over fraction for the central LV, RV, and apical
LV respectively [158] and CLV (t), CRV (t) and CAP(t) represent the corresponding time activity
curves in those regions. The apical term was added to account for temporal differences observed
between the central LV and the apical LV in swine hearts. The obtained kinetic parameters were
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not affected by the fact that decay correction was not applied to AIFs and Ctis(t) functions since
both are affected in the same way.
The model was applied on TACs obtained from PET images. For that purpose, myocardium
was segmented using available software [157] following the standard AHA 17-segment model [34],
obtaining one TAC (Ctis(t) in Eq. (6.6)) per segment. CLV (t) and CAP(t) were obtained from
spherical VOIs drawn at the central (15 mm diameter) and apical (12 mm diameter) regions of
the LV respectively, while VOI for determination of CRV (t) was manually drawn inside RV over
3–5 slices leaving a margin (> 5 mm) from the myocardium. The 5–parameter model described
on Eqs. (6.6)–(6.11) was used to fit the data from each myocardial segment with a constrained
Levenberg-Marquardt algorithm.
Figure 6.5: Kinetic compartment models followed by 68Ga-DOTA (A) and 18FDG (B) in myocardial tissue. The
model for 68Ga-DOTA is a single tissue compartment model as the radiotracer diffuses bidirectionally between in-
travascular space and extravascular extracellular space (interstitial space). The model for 18FDG is an irreversible
two-tissue compartment model as the radiotracer diffuses bidirectionally between intravascular and cellular space
and, once it enters the myocyte, it is phosphorylated to 18FDG-6-Phosphate and remains trapped since it cannot
be further metabolized.
6.3.7 In vivo versus ex vivo myocardial tissue analysis
The concentration of both tracers at the end of the PET scan (Ctis,F (tend) and Ctis,Ga(tend))
were computed for each myocardial segment using Eq. (6.6). In addition, the corresponding
relative activities (RF ,PET and RGa,PET ) as well as standardized uptake values (SUVF ,PET and
SUVGa,PET ) were also derived in the same regions at the last timeframe of the scans. In order
to validate these results, analogous measurements were obtained from myocardial tissue samples
at the same regions of the same animals that had undergone the PET examinations.
For that purpose, each animal was sacrificed at the end of the PET scans and the heart
was excised and divided into 17 segments also following AHA guidelines [34]. Each segment was
further divided into three smaller portions to obtain triplicate measurements. These 51 samples
were weighted and measured in the well counter. In order to increase the accuracy of myocardial
samples analysis, the measurements in the well counter were performed several times for each
sample for 15 hours using the full energy window (W200−2000). Measurements were corrected for
dead time and background. The counts recorded as a function of time were fitted to a sum of
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two exponential functions in order to recover the contribution from each tracer:
W200−2000(t) = WF (t) +WGa(t) = WF (t0)e−λF t +WGa(t0)e−λGa t , (6.12)
where λF and λGa are the radioactive decay constants for 18F and 68Ga respectively and WF and
WGa are the counts measured in the well counter from each isotope. WF (t0) and WGa(t0) were
fitted using Eq. (6.12) and converted to activity using the corresponding calibration factors (see
Fig. 6.4). Activity values were decay corrected at sacrifice time and the ex vivo relative activities
for 18FDG (RF ,ex vivo) and 68Ga-DOTA (RGa,ex vivo) were obtained. Results obtained on each
myocardial segment were averaged over triplicate samples. SUV values were also derived and
extrapolated to the final timeframe of the scan for each tracer (SUVF ,ex vivo and SUVGa,ex vivo).
The 18FDG relative activities derived from tissue samples (RF ,ex vivo) and from multi-tracer
PET imaging (RF ,PET ) were compared using Pearson’s correlation and the root mean square
error (RMSE), which is defined as follows:
RMSE(%) =
√√
1
N
N∑
s=1
(
RsF ,ex vivo − RsF ,PET
)2
, (6.13)
where s is the myocardial segment and N is the number of myocardial segments analyzed (N =
17). In addition, SUV values derived from multi-tracer PET imaging were compared to values
obtained from excised myocardial segments. For any statistical analysis, data are expressed as
mean ± SD unless otherwise stated.
6.4 Results
6.4.1 Tracer separation by gamma spectroscopy
The results on the calibration procedure performed to separate the contribution of 18F- and
68Ga-based tracers from blood samples containing a mixture of both tracers is presented here.
Fig. 6.2 shows a linear behavior (r2 > 0.999) between the relative activity for 68Ga (RGa) of
different 68Ga-18F mixture samples and the Q value measured in the well counter. Fig. 6.3 shows
these QS values for pure 18F and 68Ga samples with volumes ranging from 50 to 2000 µl. Of
note, the well counter detection efficiency for the high energy gamma photon emitted by 68Ga is
relatively higher at low sample volumes probably due to geometrical considerations. When the
sample volume is small, high energy events represent about 4% of the total counts for 18F samples
while it raises up to 10% for 68Ga samples. These QS(VS) profiles were fitted to a straight line
and a sum of two exponential functions respectively in order to interpolate to any given sample
volume. Fig. 6.4A shows the calibrations performed to translate the measurements obtained in
the well counter using the full energy window to activity (data shown for 18F and 68Ga). Data
presented in Fig. 6.4A were obtained from 300 µl samples. However, the calibration factors are
also volume dependent. Therefore, the calibration was repeated for different sample volumes to
account for this effect (see Fig. 6.4B).
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6.4.2 In vivo validation of multi-tracer PET against tissue analysis
Fig. 6.6A shows an illustrative AIFBS,F and AIFBS,Ga obtained from collected blood samples
that were analyzed using the gamma spectroscopy methodology previously described. The cor-
responding AIFID is shown in Fig. 6.6B as well as the dispersion-free AIFs for each tracer (AIFF
and AIFGa) that were obtained using the methodology explained in its corresponding methods
section.
Figure 6.6: A: AIFBS,F (red) and AIFBS,Ga (blue) obtained from manual blood sampling during PET scan
applying the gamma spectroscopic method. Black dashed line shows the sum of both tracers. B: AIFID (black
dashed line) obtained from the dynamic PET images using an ROI drawn in the descending thoracic aorta and
delay corrected and dispersion-free contributions from 18FDG (red) and 68Ga-DOTA (blue) obtained as detailed
in Eq. (6.5).
Fig. 6.7 illustrates myocardial tissue TACs (Ctis(t)) obtained from dynamic PET data
for each of the animals included in this study. These TACs were fitted using the multi-tracer
compartment model shown in Eq. (6.6). The separate contribution obtained for 18FDG and
68Ga-DOTA are presented in Fig. 6.6 along with the total tissue signal including the spill-over.
Fig. 6.8A shows the comparison of the relative activity for 18FDG obtained from multi-
tracer compartment modelling at the end of the PET scans (RF ,PET ) and from excised tissue
(RF ,ex vivo) for each animal and myocardial segment. A very good correlation was obtained
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Figure 6.7: Myocardial tissue TACs obtained from dynamic PET images for each animal included in this study
(black dashed lines). Data was fitted to the multi-tracer compartment model shown in Eq. (6.6) (purple line) and
separated into tissue TACs for 18FDG (red) and 68Ga-DOTA (blue).
(Pearson’s r = 0.95, p < 0.0001). Mean ± SD RF ,PET (RF ,ex vivo) obtained were 0.84 ± 0.03
(0.83 ± 0.02),0.70 ± 0.03 (0.64 ± 0.02) and 0.91 ± 0.02 (0.91 ± 0.01) for animals #1, #2 and #3
respectively. These averaged results, as well as RMSE and individualized SUVs for 18FDG and
68Ga-DOTA contributions are presented in Table 6.1. SUV values obtained for 68Ga-DOTA
were similar in all animals. SUVGa is low (∼0.3) because this tracer reaches equilibrium between
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the plasma and the interstitial space and therefore, the tracer does not accumulate in tissue.
On the other hand, low SUVF ,PET were obtained for animals #1 (0.97) and #2 (0.62) while
higher values were obtained in the third animal (2.54). These SUV values are highly correlated
(Pearson’s r = 0.98, p < 0.0001) with those obtained from excised tissue (SUVF ,ex vivo and
SUVGa,ex vivo). The higher SUVF of the third animal agrees with lower RMSE values obtained
for this animal since higher uptake lead to lower statistical noise in the pharmacokinetic analysis,
as well as in the measurements performed on excised tissue. In all cases obtained RMSE values
were below 7%.
Figure 6.8: Linear correlation between relative activities for 18FDG (A) and between SUVs for both 18FDG and
68Ga-DOTA (B) obtained from multi-tracer compartment modelling at the last frame of the PET scan (RF ,PET ,
SUVPET ) and from excised tissue (RF ,ex vivo, SUVex vivo). Each dot represents one of the 17 myocardial segments
for each animal. The results are highly correlated (r = 0.95, p < 0.0001 for relative activities and r = 0.98,
p < 0.0001 for SUVs).
Table 6.1: Relative activities and SUVs obtanied with PET and ex vivo tissue analysis.
Animal RF ,PET a RF ,ex vivo RMSE(%)b SUVGa,PET c SUVGa,ex vivo SUVF ,PET SUVF ,ex vivo
#1 0.84 ± 0.03 0.83 ± 0.02 3.6 0.30 ± 0.07 0.51 ± 0.09 0.96 ± 0.15 1.56 ± 0.14
#2 0.70 ± 0.03 0.64 ± 0.02 6.8 0.27 ± 0.08 0.39 ± 0.03 0.60 ± 0.16 0.65 ± 0.03
#3 0.91 ± 0.02 0.91 ± 0.01 1.7 0.28 ± 0.05 0.54 ± 0.06 2.55 ± 0.26 4.65 ± 0.36
RF ,PET and RF ,ex vivo values are represented as the mean ± SD of all the myocardial segments analyzed for each animal
along with their comparison obtained using the RMSE value. Mean ± SD SUV for each tracer obtained from multi-tracer
PET analysis and excised tissue are also shown.
a RF : 18FDG relative activity.
b RMSE(%): Root-mean square error expressed as a percentage.
c SUV : Standardized uptake value.
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6.5 Discussion
The methodology described above allows explicit measurement of a separate AIF for each tracer
while other existing methods rely on AIFs based on representative patients [105] or using extrap-
olation techniques [182]. Our technique requires using at least one tracer based on a non-pure
positron emitter. The analysis is based on the different energy spectra of the emission of the two
radiotracers involved. A spectroscopic analysis of blood samples containing both tracers can be
performed in order to obtain the concentration of each individual tracer. This technique is able
to resolve the individual contribution of the two radiotracers when the energy of the additional
gamma rays emitted by the non-pure positron emitter differs from the energy of annihilation
photons. This fact, however, rules out the possibility of combining tracers based on the same
isotope, or both tracers based on pure positron emitters such as 18F or 15O. On the other hand,
68Ga, with its high-energy emission at 1.077 MeV, can become a suitable wildcard isotope for this
technique. 68Ga has emerged as a very promising isotope for PET imaging with many relevant
applications in clinical diagnosis [195]. Therefore, further combinations of tracers based on 18F
and 68Ga, different from that shown in this study, might benefit from this work, and this is the
reason why the combination 18FDG–68Ga-DOTA was chosen for this work.
In this chapter, we developed a calibration procedure that allows the determination of in-
dividual tracer concentration of samples containing an unknown mixture of the isotopes used in
this study (18F and 68Ga). For that purpose, samples were analyzed in a well counter recording
events at two energy windows. The ratio between the counts recorded in both energy windows
was later employed to determine the relative activity of each isotope. Corrections were made to
account for different sample volumes (see Fig. 6.3). A 45 min dynamic PET scan was performed
on each animal and blood samples were collected during the entire acquisition and further ana-
lyzed with the well counter to determine the AIF for each tracer. A multi-tracer compartment
model was later applied to recover the individual tissue TAC for each tracer on individual my-
ocardial segments (see Fig. 6.7). Radiotracer concentrations at the last timeframe of their PET
scan were validated against both 18FDG and 68Ga-DOTA concentration measured with the well
counter on excised myocardial tissue. Results show that the proposed multi-tracer PET imaging
technique offers very similar results to those obtained as a reference from ex vivo analysis (see
Fig. 6.8), with RMSE below 7% in all cases. Moreover, SUV for 68Ga-DOTA and 18FDG were
obtained showing normal 68Ga-DOTA uptake for healthy pigs [214] and variable 18FDG uptake
as expected, since no prior glucose load was used [126]. An overestimation of SUVex vivo values
compared to SUVPET values can be observed, which might be explained by partial volume effect
in PET data.
There are other techniques that use non-pure positron emitters with prompt gamma emis-
sions and utilize the PET scanner to record coincidence events containing annihilation and
prompt-gamma photons. These prompt-gamma photons are later used in the reconstruction
process to separate the contribution from each tracer [5]. However, a very large branching ratio
of the prompt gamma photons is required to obtain enough sensitivity of this type of events and
therefore, those techniques are limited to less common isotopes like 124I. It should be noted that
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in the proposed method, the additional photons emitted by the non-pure positron emitter are
not required to be emitted promptly. They can be delayed with respect to the positron decay as
they do not have to be detected in coincidence for the spectroscopic analysis.
Finally, it must be noted that in this study, the spectroscopic analysis of the blood samples
was performed using a well counter. However, an online blood sampling detector [31, 178] could
be also used, which would further simplify the implementation of this technique. In that case,
blood would be extracted from the patient through a catheter that passes through a gamma
photon detector and a similar methodology to the one applied with the gamma counter would
be used. In that way, AIF separation could be obtained immediately while minimizing the
radiation exposure of the personnel and avoiding technical issues such as volume dependence of
blood samples.
6.6 Conclusions
In this chapter we proposed a novel technique to PET scans with two tracers during the same
acquisition using multi-tracer compartment modelling. It is based on the explicit separation of
individual AIF based on a spectroscopic analysis of the emission spectra of each tracer. The pro-
posed technique was implemented in vivo by performing cardiac PET/CT studies on 3 healthy
pigs, which were injected with 18FDG and 68Ga-DOTA during the same acquisition and success-
fully validated against their analogous ex vivo measurements.
78 Chapter 6: Multi-tracer PET using blood sampling spectroscopy
7
A BLOOD SAMPLING DETECTOR FOR MULTI-TRACER PET
7.1 Introduction
In the previous chapter, we proposed and evaluated a new technique for multi-tracer PET imaging
based on blood spectroscopic analysis. With this method, the radioactivity emitted from each
radioisotope could be detected, providing independent AIFs for each radiotracer.
The spectroscopic analysis tested in vivo was carried out by measuring the energy spectra
of a set of time-ordered blood samples manually withdrawn from the animals. However, AIF
obtained from a set of blood samples may lack a good time resolution and is limited by the
rate at which the technologist can obtain those samples. Additionally, manual blood sampling
implies an increase of radiation exposure of the operating personnel and is more prone to error
as it requires rapid manual handling.
To address these issues, several automatic blood sampling devices with a radioactivity de-
tector integrated have been developed over the years. They are based on either positron [38,
117] or annihilation photon detection. Most of these gamma detection devices use scintillation
crystals (such as BGO [27], GSO [223], NaI [156] or LYSO [178]) coupled to a photomultiplier
tube (PMT). However, alternatives to PMT have also been proposed, such a CZT-based device
[56] and a LSO crystal coupled to an avalanche photodiode (APD) [31], which is more compact
and can operate under magnetic fields, although APD gain is highly temperature dependent.
In this chapter, we propose an online blood-sampling detector made with two detectors based
on silicon photomultipliers (SiPMs) and CsI(Tl) scintillation crystals working in coincidence.
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SiPMs are compact, MR-compatibles, inexpensive, can be operated at low voltage, and have a
very high gain. CsI(Tl) has been selected for its high detection efficiency, high light yield and
absence of intrinsic radioactivity, which allows performing measurements in single and coincidence
modes making it suitable for PET and SPECT radiotracers.
Moreover, our prototype not only provides the live photon count rate emitted from the
blood, but also stores and analyzes the gamma energy spectrum of each event recorded during
the acquisition (either single or coincidence). This feature makes possible to determine the
AIF even when there is more than one radiotracer circulating in blood and makes possible to
distinguish the individual contributions of each radiotracer to the total AIF by using the blood
spectroscopic analysis described in the previous chapter.
7.2 Aim of the chapter
The aim of this chapter is to design, develop and characterize the blood sampling detector
described above. We evaluated in vivo its performance and tested its capability for separation
of dual AIFs using the spectroscopic analysis described in the previous chapter.
7.3 Methods
7.3.1 Blood sampling detector design
The blood sampling detector consists of two detection units, each one made with a 50 × 50 ×
25 mm3 CsI(Tl) scintillation crystal with diffuse surfaces (Scionix Holland, Bunnik, The Nether-
lands) wrapped with a white diffuse plastic reflector. On the center of one of the 50 × 25 mm2
faces, an area of 4 × 4 mm2 is left unwrapped for optical readout. Each crystal is coupled with
optical grease to a SiPM (ASD-RGB4S-P, AdvanSiD, Trento, Italy) with an active area of 4
× 4 mm2 operated at 31 V. SiPMs are connected to amplification boards based on inverting
transimpedance amplifiers. Crystals are placed side by side along one of the 50 × 50 mm2 faces
with an 11.5 mm gap between them (see Fig. 7.1). The crystals, SiPMs and readout electronics
are placed within a 3D-printed enclosure. The blood sampling catheter is placed in the center of
the gap between crystals in a 3D-printed U-grooved holding cassette. This piece can be fixed to
the detector enclosure (see Fig. 7.1), allowing for measurements in single and coincidence modes
and ensuring a good reproducibility. The detector shielding is made of a double layer of 3 cm
thick lead bricks in order to minimize the detection of external radiation.
7.3 Methods 81
Figure 7.1: External (A) and internal (B) views of the blood sampling detector developed in this study. The
device consists of two 50 × 50 × 25 mm3 CsI(Tl) scintillation crystals (blue boxes) coupled on one of the 50 ×
25 mm2 faces to a 4 × 4 mm2 SiPM (hidden in this illustration). Crystals are placed at 11.5 mm distance. The
catheter (red tube) is placed in the gap between crystals with a holding cassette (white piece).
7.3.2 Data acquisition and signal processing
The signals from both detection units are digitized (15 MS/s) with an oscilloscope (Picoscope
Series 2206A, Pico Technology Ltd, Cambridgeshire, UK) and sent to a PC for further processing
using a custom-made application based on the oscilloscope’s C++ API. All pulses triggered by
a falling edge discriminator are integrated for 2 µs to obtain the energy deposited by the gamma
photons and stored as single events for each detector. The signal is also recorded for 1 µs pre-
trigger, and this part is used for baseline correction. Time stamps are generated by the leading-
edge discrimination in both detectors. Single events with a time difference below 300 ns are also
stored as coincidence events. Random coincidences are estimated and subtracted through the
singles rates using standard procedure. Environmental background events are subtracted from
single and coincidence events. For that purpose, a 2 hour measurement with no activity in the
catheter is used.
7.3.3 Device characterization
Sensitivity, energy resolution, coincidence resolving time and count rate losses
In order to characterize the detector, a 0.8 mm internal diameter (ID) catheter (Tygon S3 E-3603,
Saint-Gobain Performance Plastics Co., Akron, OH, USA) was filled with 18FDG at an initial
activity concentration of 900 kBq/mL and placed in the blood sampling detector with the active
length centered with the detection units. A 15 hour acquisition was performed consisting in 150
frames of 1 minute duration with 5-minute gap intervals. The energy spectra were obtained and
calibrated using the 511 keV peak for every acquisition in order to compensate for temperature-
dependent gain variations. The energy resolution at the 511 keV photopeak was obtained by
fitting to a gaussian.
Sensitivity was computed as the slope of the linear fit of the events rate (singles or coinci-
dences) measured within an energy window of 350–700 keV against their corresponding activity
concentration. This fit was performed for the low count rate measurements. Count rate losses
were estimated for single events assuming that no events are lost at low count rate. Coincidence
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resolving time (CRT) was derived from a gaussian fit of the detection time difference histogram
for coincidence events within the same energy window of 350–700 keV.
Minimum detectable activity
Minimum detectable activity (MDA) determines the smallest activity concentration that can be
detected with a certain confidence level [40]. MDA depends on sensitivity of the detector (s),
the duration of the measurement (T), and background events (NB) detected during T . In terms
of kBq/mL, and at a 95% confidence level, MDA can be described as:
MDA =
4.65
√
NB + 2.71
Brβ+Ts
, (7.1)
where Brβ+ is the branching ratio for β+ decays (0.967 for 18F). NB was measured with and without
the presence of an external source of activity. In the first case, only the environmental radiation
contributes to background radiation, whereas in the second case, the radiation emitted from the
patient itself can penetrate the shielding and contribute to background signal. Consequently,
MDA was determined in both scenarios for both single and coincidence events using an energy
window of 350–700 keV. Details about the setup employed for the background measurements
with an external activity source are given in the following section. In each case, background
measurements of 2–3 minutes were performed in three independent acquisitions. The results are
presented as mean ± SD.
7.3.4 In vivo evaluation
The performance of the blood sampling detector was evaluated in vivo in animals injected with
18FDG. The study was conducted according to the guidelines of the current European Directive
and Spanish legislation and approved by the regional ethical committee for animal experimenta-
tion. In this case, three healthy female LArge White pigs (mean weight = 45 ± 4 kg) were anes-
thetized by intramuscular injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and midazolam
(0.5 mg/kg), and maintained by continuous intravenous infusion of ketamine (2 mg·kg−1·h−1),
xylazine (0.2 mg·kg−1·h−1), and midazolam (0.2 mg·kg−1·h−1). Oxygen saturation levels and
ECG were monitored throughout the study. The coccygeal artery of the animal was cannulated,
and arterial blood was withdrawn through a 0.8 mm ID catheter at 5 ml/min using a peristaltic
pump. The animals received a bolus injection of heparin and the catheter was washed with hep-
arinized saline to prevent clotting. The animal was placed in a PET/CT Gemini TF-64 scanner
(Philips Healthcare, Best, The Netherlands) and the scanner table was moved to the position
were cardiac PET acquisitions are routinely performed. The detector was placed at about 40
cm from the animal’s tail in order to minimize blood dispersion inside tubing. 18FDG (155 ±
12 MBq) was prepared in 6 ml and infused at a rate of 1.0 ml/s through a marginal ear vein,
followed by a 6 ml saline flush at the same rate. The acquisition with the detector started with
the dose injection and lasted for 5 minutes. The AIF was obtained with the detector (AIFD)
in consecutive 5 second frames using the single events recorded in the 350–700 keV energy win-
dow and converted to activity concentration using the sensitivity obtained from the previous
7.3 Methods 83
characterization of the detector. Afterwards, measurements for MDA determination with an ex-
ternal source of activity were performed by placing an empty catheter in the device and leaving
everything else in the same position. Also, decay correction was applied.
In order to validate AIFD results, blood samples were collected after passing through the
blood sampling detector (at the end of the catheter). Withdrawn blood was collected into sample
tubes according to the following temporal scheme: 20 × 5 s, 8 × 10 s, 6 × 20 s. Then, the tubes
were briefly centrifuged to provide a reproducible geometrical distribution of the blood and
later analyzed with a well counter (Wallac 1470 Perkin Elmer, Waltham, MA, USA) applying
dead time and decay corrections. The well counter had been previously calibrated to convert
measurements to activity values as detailed in Chapter 6. The volume for each blood sample
was determined as the weight difference between empty and filled tubes and considering a blood
density of 1.03 g/ml [179]. Finally, the activity concentration of 18FDG was calculated for
each blood sample obtaining the AIF derived from the well counter (AIFWC). The time delay
existing between AIFD and AIFWC was corrected by maximizing the cross-correlation between
both curves, which had been previously interpolated every 5 seconds.
7.3.5 Multi-tracer AIF detection by spectroscopic analysis
Pure β+-emitter isotopes such as 18F only emit 511–keV annihilation photons, while non-pure
β+ isotope like 68Ga emit additional photons, although only those emitted at 1.077 MeV have a
significant contribution (3.22%). Thus, the ratio of events recorded at high–energy (> 750 keV)
and low–energy windows (350–700 keV) (see Fig. 7.2) can be used to determine the amount of
18F and 68Ga in a sample containing any combination of both isotopes.
Figure 7.2: Normalized energy spectra of single events recorded from 18F (pure β+-emitter, red) and the 68Ga
(non-pure β+-emitter, blue) shown in linear (A) and logarithmic (B) scales. The green and orange boxes represent
the energy windows set at [350, 700] and [750, 2000] keV to distinguish between photopeak (low energy) and high-
energy events. The events recorded within the high energy window are relatively higher for 68Ga than for 18F
compared to the events recorded in the photopeak.
Two acquisitions were performed so as to obtain the calibration data required to implement
the proposed method. A 0.8 mm ID catheter was filled with 68Ga or 18F respectively with an
initial activity concentration of 1200 kBq/mL (measured with an activimeter). Afterwards, the
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catheter was placed in the blood sampling detector and data was recorded for several hours
acquiring frames of 1 minute with 5-minute gap intervals. Each frame was processed to obtain
the total SR at high energy window (750–2000 keV, SHE) and the coincidences rate at low
energy window (350–700 keV, CLE). The ratio between SHE and CLE could be used, in theory,
to calibrate the measurements for each isotope. However, we observed that, at higher count
rates, the increase of SHE is not proportional to CLE due to pile-up events. Therefore, in order
to include this effect in the calibration, SHE must be calibrated as a function of CLE . For
that purpose, the variation of SHE against CLE was represented and fitted to a third-degree
polynomial for each isotope (SHE ,F (CLE) and (SHE ,G(CLE) for pure 18F and 68Ga respectively).
When measuring SHE and CLE for a sample containing an unknown mixture of 18F and 68Ga
(SHE ,Mix), the relative activity of each isotope (aGa,D and aF ,D, being aF ,D + aGa,D = 1) can be
obtained using the following expression:
SHE ,Mix(CLE ) = aGa,D · SHE ,G(CLE ) + (1 − aGa,D) · SHE ,F (CLE ) , (7.2)
assuming that the contribution of pile-up events is equally distributed between both isotopes.
The ability of the developed detector to obtain separated AIFs of tracers labelled with
different isotopes (68Ga and 18F) was tested in vitro. For that, a catheter filled with a mixture of
73% 68Ga and 27% 18F with an initial total activity concentration of 1200 kBq/mL was placed
in the detector. The activity was measured separately for each isotope with an activimeter and
the mixture was prepared afterwards. Data were recorded for several hours acquiring frames
of 1 minute duration with 5-minute gap intervals. The relative activity of both isotopes was
constantly changing over time due to their different half-lives (∼110 min for 18F and ∼68 min for
68Ga).
The initial activity concentration (C(ti) = 1200 kBq/ml) was much higher than the typical
values that can be measured in an AIF of an in vivo experiment on large animals. In those
studies, the activity concentration usually ranges between 10 and 200 kBq/mL, and the duration
of the timeframes of the dynamic PET acquisition are frequently set from 5 seconds (in those
frames where the activity concentration is high and changes rapidly) up to 60–180 seconds
(for those frames where there activity concentration is low and the changes over the time is
less significative). Hence, in order to evaluate our experiment in more realistic conditions, our
1 minute acquisitions were trimmed (and only the first t ′ seconds of acquisition were used)
depending on the activity concentration of each acquisition as follows:
t ′ =

60 s ,when max (C(t)) < 10 kBq/ml
10 s ,when 10 kBq/ml ≤ max (C(t)) < 50 kBq/ml
5 s ,when 50 kBq/ml ≤ max (C(t))
. (7.3)
SHE ,Mix and CLE were obtained for each frame and aGa,D was calculated using Eq. (7.2). These
results were compared against known values (aGa,A) obtained from their initial activity and their
half-lives. The mean relative difference between aGa,D and aGa,A was obtained and reported as
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a percentage.
7.4 Results
7.4.1 Detector performance and in vivo evaluation
The energy resolution and the CRT of the blood sampling detector was determined using one of
the acquisitions performed at low count rate obtaining 35% FWHM at 511 keV (see Fig. 7.2)
and 174 ns FHWM (see Fig. 7.3) respectively. The count rate losses for single events are shown
in Fig. 7.4. Fig. 7.4A displays the recorded SR as a function of the activity concentration within
the catheter and Fig. 7.4B illustrates the deviation of measured SR from the expected value
as a function of the activity concentration. In can be seen that, for an activity concentration
within the range of standard in vivo experiments (10–400 kBq/mL), the count-rate losses are
below 2%. Random coincidences were also computed and can be considered negligible (< 0.3%).
The sensitivities obtained for single and coincidence events were 22.6 cps·kBq−1·ml−1 and 1.7
cps·kBq−1·ml−1 respectively.
Figure 7.3: Time difference histogram obtained with the blood detector using 18F for a 1 minute acquisition with
an energy window of 350–700 keV. The line represents the gaussian fit of the histogram, leading to a FWHM of
175 ns.
The MDA was computed for single and coincidence events with and without an external
activity source. In the absence of an external source, the MDA was 0.05 ± 0.02 kBq/mL (singles)
and 0.10 ± 0.03 kBq/mL (coincidences) while the results with an external source were 0.30 ±
0.08 kBq/mL (singles) and 0.25 ± 0.05 kBq/mL (coincidences).
Fig. 7.5 shows the AIFs obtained with our detector (AIFD) from three in vivo studies in
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Figure 7.4: A: Singles rate detected by the device as a function of activity concentration (c, red dots) inside the
catheter. A linear fit of the measured SR at low c when count rate losses are negligible is also shown (blue dashed
line). B: Count rate losses (δSR) as a function of activity concentration.
which blood was withdrawn at a rate of 5 ml/min from a 0.8 mm ID catheter. An excellent
correlation between AIFD and the blood samples analyzed with the well counter (AIFWC) was
found (r = 0.996, p < 0.0001).
Figure 7.5: AIFs obtained with the blood sampling detector (AIFD, red curves) compared to the AIFs obtained
from collected blood samples analyzed in a well counter (AIFWC , black curves) on three pigs that were injected
with 18FDG. The Pearson’s correlation obtained in all cases is excellent (mean r = 0.996, p < 0.0001).
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7.4.2 Multi-tracer AIF separation by spectroscopic analysis
Fig. 7.6 shows the calibration curves performed for the in vitro measurements of pure 18F and
pure 68Ga (SHE ,F and SHE ,G respectively) as well as the high energy SR corresponding to an
unknown mixture of these radioisotopes (SHE ,Mix). It can be observed that the SHE ,Mix dataset
gets closer to the pure 18F measurements for lower CLE as 18F activity decreases slower than
for 68Ga and consequently the relative activity of 18F increases over time. All datasets tend to
SHE = 0 at low activity concentrations, which confirms that the background subtraction to every
acquisition has been performed correctly.
Figure 7.6: Singles rates measured within the high energy window (SHE) as a function of the coincidence rate
measured inside the low energy window (CLE) for measurements performed with pure 18F (red dots), pure 68Ga
(blue dots), and a mixture of both radioisotopes (black dots). The results for the pure samples were fitted to a third-
degree polynomial (blue and red lines for pure 68Ga and 18F respectively). These fits are used as the calibration
curves named as SHE ,F and SHE ,Ga in Eq. (7.2)).
The relative activity of 68Ga in the mixture was calculated using Eq. (7.2) and the compar-
ison against the known values shows a very strong correlation (r = 0.97, p < 0.0001, Fig. 7.7).
The mean relative difference between aGa,D and aGa,A was δ = (3± 10)%. When the acquisition
was trimmed as described in Eq. (7.3) to analyze more realistic activity concentrations and
timeframe duration, the correlation was still very good (r = 0.91, p < 0.0001), with only a slight
increase in the variation of the mean deviation from the true values (δ = (2 ± 13)%).
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Figure 7.7: Comparison between the relative activity of 68Ga obtained with the blood sampling detector using the
gamma spectroscopy analysis of a mixture of 68Ga and 18F (aGa,D) and the known relative activity (aGa,A). The
data collected from the 1 min acquisitions were analyzed entirely (gray squares) and partially (following scheme
given in Eq. (7.3), black dots). Pearson’s r correlation of the datasets with the true values (aGa,A) are r = 0.97
and r = 0.91 respectively. Dashed blue line represents the identity line.
7.5 Discussion
The results show that the detector presented in this study has a high sensitivity, and it can obtain
accurate and stable measurements of AIFs under realistic conditions. The device can work within
a wide range of activity concentrations (up to 400 kBq/mL with dead-time losses below 2%, Fig.
7.4) and presents a very low MDA for both single and coincidence events (0.25 and 0.30 kBq/mL
respectively) in presence of an external activity source. The device is potentially MR-compatible
thanks to the SiPM-based detection system, although few minor changes (connectors, electronic
components, . . . ) would be required to enable this option. The in vivo performance of the device
has been studied with three pigs leading to an excellent correlation (mean correlation r = 0.996,
all with p < 0.0001) between the AIFs obtained with the device and those obtained from the
analysis of collected blood samples in a well counter.
The configuration parameters used in these studies, such as activity concentrations, tubing
size and timeframe scheme are similar to those used in human studies. Therefore, this device
would be suitable for utilization in the clinical routine. In case of studies with rats, the inner
diameter of the tubing usually ranges from 0.18 to 0.64 mm, which translates into a reduction
of 60 to 95% of the active volume. However, the injected dose per gram for rats is about 30
times higher than for humans. Therefore, our device could also be used in rat studies as similar
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count rate to that obtained in pig studies is expected. Moreover, the blood withdrawal rate could
be reduced proportionally to the catheter volume reduction [31] while keeping a similar blood
renewal rate in the active length of the device. For example, for a 0.18 mm ID tubing, blood
could be withdrawn at a rate of 0.25 ml/min with similar accuracy to the results presented in
this work.
When measuring AIF with a blood sampling detector, blood activity dispersion inside the
tubing reveals as a critical factor that may introduce large errors in the final quantification.
Many approaches have been proposed to correct dispersion issues [94, 142, 150] analytically, but
it is still advisable to minimize the main sources or dispersion in the experimental setup, such
as tubing length or blood withdrawal rate. In this aspect, the compact design of the device
as a consequence of the use of SiPM detectors makes possible to place it in close proximity to
the subject, which turns into a reduced blood dispersion effect. Furthermore, the capability of
the detector to record coincidence events reduce the background events detected from external
sources.
Finally, a blood sampling spectroscopic analysis similar to the one proposed in the previous
chapter was tested using the blood sampling detector with mixtures of a pure β+-emitter (18F) and
a non-pure β+-emitter (68Ga). The detection of additional gamma photons emitted by 68Ga (see
Fig. 7.2) permitted to disentangle the activity of each radioisotope. The poor energy resolution
(35% FWHM at 511 keV) and CRT (174 ns FWHM) obtained is due to the large difference
between the size of the SiPMs (4 × 4 mm2) and the size of the scintillation crystal (50 × 50 ×
25 mm3). Although the energy resolution is not a critical factor for standard blood sampling
analysis, it may limit the accuracy for blood sampling spectroscopy. However, validation results
shown on Fig. 7.7 demonstrate the capability of the developed device to separate (with a very
good correlation, r = 0.91, p < 0.0001) the contribution of 18F and 68Ga for a sample containing
a mixture of both isotopes. Nevertheless, the CRT did not affect to the device performance as
the obtained fraction of random events was very low in all cases.
7.6 Conclusions
We have developed a blood sampling detector based on SiPM technology capable of recording
simultaneously single and coincidence events with different energy windows. The performance
parameters of this detector have been obtained leading to excellent results compared with other
devices presented in the literature. The detector has been tested in vivo with several pigs
injected with a single radiotracer and the results were validated showing excellent results. To our
knowledge, available blood sampling detectors can only measure single-tracer AIFs. In contrast,
a gamma spectroscopic analysis technique has been successfully implemented and validated in
our detector for its application in multi-tracer PET studies when one of the radiotracers is based
on a non-pure β+-emitter. Therefore, the device presented in this study allows performing fully
automatic single- and multiple-tracer PET studies. Moreover, this is the first blood sampling
detector based on SiPM technology which offers many advantages in terms of cost, compactness,
performance and MR-compatibility.
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CONCLUSIONS
The original aim of the work carried out throughout this dissertation was not to give an answer
to certain scientific questions, but rather to offer new possibilities in the PET field so as to
widen its worldwide availability. Consequently, during this conclusion section, a list of answers
to particular hyphoteses will not be provided; instead an enumeration of the tools proposed
and developed, along with the benefits they may provide to the scientific community, will be
enumerated.
i. The novel PET radiotracer 68Ga-DOTA has been successfully proposed as a myocardial
blood flow tracer. Its feasibility has been demonstrated and validated in pigs under different
rest-stress conditions against a perfusion gold standard.
ii. The same tracer, 68Ga-DOTA, has also been proposed to be used as an estimator of myocar-
dial viability. The ability to distinguish healthy and ischemic regions of infarcted hearts has
been tested in pigs that had undergone a myocardial infarction.
iii. 68Ga-DOTA has also been proposed as a pulmonary blood flow PET radiotracer. It has
been validated against a perfusion gold standard in healthy pigs under rest condition.
iv. A new method for multiple-tracer PET imaging has been proposed, implemented and vali-
dated. It is based on the gamma spectroscopic analysis of blood samples that may contain
more than one radiotracer. The feasibility of separating the signal coming from both tracers
is linked to the utilization of a non-pure beta emitter radionuclide as the labeling agent of
at least one of the radiotracers.
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v. A new blood sampling detector has been developed to carry out the proposed multi-tracer
PET spectroscopic analysis. The detector has been characterized and tested under realistic
clinical PET experimental conditions. The capability of the detector to explicitly separate
the signal emitted from both radiotracers has also been evaluated and validated.
Here we present the impact that these conclusions may have in the expansion of cardiac
PET worldwide:
I. The short half-life together with the high cost of production of the radiotracers used for
MBF assessment has hindered a broader application of PET in clinical cardiology, despite
its superlative diagnostic value. A radiotracer like the one proposed in this thesis (68Ga-
DOTA) could overcome those limitations, since it can be produced from a long duration
benchtop generator. Moreover, its half-life of 68 min facilitates its regional distribution, thus
eliminating the need of having a 68Ge/68Ga generator in every hospital. These economical
advantages, together with its demonstrated feasibility as a radiotracer for MBF and viability
assessment, could translate into a worldwide spread of cardiac PET imaging.
II. The confirmed capability of 68Ga-DOTA to quantify PBF enlarges its versatility as a per-
fusion tracer. Moreover, following the examples provided in this thesis, new perfusion
applications may be found for this radiotacer. A wider range of 68Ga clinical applications
could motivate the hospitals to undertake the investment in a 68Ge/68Ga generator.
III. Multi-tracer PET is capable of reducing the scanning time (from hours or days to min-
utes) of cardiac studies in which MBF assessment and viability are required, via rest-stress
tests and FDG scans, respectively. In addition, multi-tracer PET eliminates misalignment
problems that may appear when repeating single-tracer scans in different sessions. These
advantageous properties could translate into an increase in the patient throughput, thus
leading to improved cost-effectiveness of PET.
IV. The spectroscopic analysis in which our proposed multi-tracer PET technique is based does
not need human intervention. A blood detector, such as the one presented in this work,
may be used in order to minimize radiation exposure of the technical personnel. This could
encourage the implantation of multi-tracer PET in the clinical setting.
Taking into account the statements enumerated above, we firmly believe that the work
presented throughout this thesis will contribute to some extent to the expansion of positron
emission tomography in the clinical practice.
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APPENDIXC
ADVANCED IMAGING TECHNIQUES FOR CARDIOVASCULAR RESEARCH
ABSTRACT
Introduction
According to the World Health Organization, cardiovascular diseases (CVDs) are the first cause
of death globally. CVDs are a cluster of disorders that involve heart and blood vessels. Among
them, coronary artery disease (CAD) is the most important disease in terms of mortality, causing
more than 50% of the annual deaths. Over the last decades, many recognized international
organisms, such as the World Health Organization and the American College of Cardiology have
done great efforts to reduce the mortality and morbidity of CAD. In this line, accurate diagnosis
and cost-effective management of CAD have revealed to be of utmost importance.
Several imaging techniques are currently used in the clinical practice to provide a diagnosis
and clinical assessment of the disease. Among them, Positron Emission Tomography (PET) is
considered to be the “gold standard” for noninvasive assessment of myocardial perfusion and
viability, the two most relevant physiological parameters used to diagnose and manage patients
with known or suspected CAD.
However, despite its unquestioned diagnostic value, PET still faces several difficulties to-
wards its expansion as a clinical tool utilized worldwide. This is due to factors such as the
high cost of the scanners and the extremely low availability of the radiopharmaceuticals required
to perform the tests (mainly due to their cyclotron-based production pathway and their short
half-lives).
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Objectives
In this thesis we addressed some of those difficulties by exploring new applications of a 68Ga-
labeled radiotracer (68Ga-DOTA). 68Ga can be obtained from a 68Ge/68Ga generator and has a
half-life of 68 minutes, which makes it a convenient candidate for its widespread clinical use.
We proposed and validated the use of 68Ga-DOTA as a radiotracer for assessment of my-
ocardial blood flow (MBF), myocardial viability and pulmonary blood flow (PBF). Additionally,
we introduced a new methodology to perform a PET scan in which this tracer could be co-
injected simultaneously with some other radiotracers such as 18FDG (multi-tracer PET). Lastly,
we developed an automatic detector able to perform blood spectroscopy analysis, which offered
the possibility to perform multi-tracer PET with minimal human intervention.
Methods
To test the capability of 68Ga-DOTA to measure MBF, viability and PBF, different groups of
Large White pigs underwent PET/CT scans using 68Ga-DOTA as the injected radiotracer. For
PBF studies, a group of healthy pigs (n = 4) were scanned under rest conditions. For MBF
studies, a group of 8 pigs were scanned under rest and pharmacologically-induced stress in order
to perform rest/stress tests, as it is done for humans in clinical routine. Additionally, a group of
5 pigs were scanned 7 days after the induction of a myocardial infarction (MI) to assess viability
and MBF in a MI model.
MBF, extracellular volume fraction (ECV, for viability assessment) and PBF maps were
obtained after fitting the dynamic PET images to the corresponding pharmacokinetic model
followed by 68Ga-DOTA in each tissue under study. Global and regional perfusion maps for the
myocardial tissue (MBF) and lungs (PBF) were obtained. For validation purposes, the “gold-
standard” technique used in tissue perfusion quantification (fluorescent-labeled microspheres
(MS)) was simultaneosly performed along with the PET/CT scans.
The blood sampling spectroscopic methodology was evaluated and calibrated in vitro using
different 68Ga/18F mixtures. Then, it was tested in pigs (n = 3) injected with 68Ga-DOTA and
18FDG in the same acquisition. The activity concentration of each radiotracer in myocardial
tissue was subsequently measured ex vivo.
The automatic blood sampling detector was built from scratch and characterized using a
catheter filled with different 68Ga/18F mixtures. Finally, it was additionally evaluated in vivo in
n = 3 pigs under conditions resembling to those encountered in clinical routine.
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Results
Regarding MBF quantification and validation with 68Ga-DOTA-PET, a strong correlation (r =
0.91) between MBF measured with PET and MS was obtained (slope = 0.96 ± 0.10, y-intercept
= 0.11 ± 0.19 ml·min−1·g−1). For the myocardial infarction model, MBF values obtained with
68Ga-DOTA-PET in the infarcted area (LAD, left anterior descendant) were significantly reduced
in comparison to remote ones LCX (left circumflex artery, p < 0.0001) and RCA (right coronary
artery, p < 0.0001). In addition, 68Ga-DOTA-PET detected a significant ECV increase in the
infarcted area (p < 0.0001).
The correlation evaluation between 68Ga-DOTA-PET and MS as a PBF radiotracer also
showed a good and significant correlation (r = 0.74, p < 0.0001).
The gamma spectroscopic analysis on blood samples proposed for multi-tracer PET imag-
ing was also succesfully validated, showing a correlation of r = 0.95 (p < 0.0001) for 18FDG
concentration in myocardium measured with multi-tracer PET and by ex vivo validation.
The blood sampling detector was able to measure the arterial input function in pigs in an
experimental setup under realistic conditions.
Discussion and conclusions
68Ga-DOTA-PET allowed accurate non-invasive assessment of MBF and ECV in pigs with my-
ocardial infarction and under rest-stress conditions. This technique could provide wide access
to quantitative measurement of both MBF and ECV with PET imaging. 68Ga-DOTA-PET was
also demonstrated to be a potential inexpensive method for measuring PBF in clinical settings.
As for multi-tracer PET imaging, the proposed methodology allowed explicit measurement
of separate arterial input functions, offering very similar results to those obtained as a reference
from the ex vivo analysis of the tissue under evaluation.
Finally, a novel blood sampling device was developed and characterized, showing perfor-
mance parameters similar to other devices in the literature. Noteworthy, this detector has the
additional and unique feature of allowing us to perform multi-tracer PET by means of a gamma
spectroscopic analysis of the blood flowing between its detection blocks.
All the results summarized in this abstract may contribute to spread the use of PET in
clinical routine, either by the clinical use of 68Ga-DOTA as an inexpensive but accurate radio-
tracer for MBF, PBF or viability assessment, or by the implementation of multi-tracer PET,
which could lead to cost reduction of PET examinations by shortening the scanning time and
eliminating misalignment inaccuracies. This multi-tracer PET methodology could also be safely
implemented using our proposed automated device that permits to perform the gamma spectro-
scopic analysis on blood samples with minimal human intervention.
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APPENDIXD
TE´CNICAS DE IMAGEN AVANZADA APLICADAS A LA INVESTIGACIO´N CARDIOVASCULAR
RESUMEN
Introducción
Según la Organización Mundial de la Salud (OMS), las enfermedades cardiovasculares son, cada
año, la primera causa de muerte en el mundo. De ellas, más de la mitad son causadas por la
enfermedad de las arterias coronarias. En las últimas décadas, numerosos organismos interna-
cionales de reconocido prestigio, como la propia OMS o el Colegio Americano de Cardiología,
han centrado sus esfuerzos en reducir la mortalidad y la morbilidad de esta enfermedad y han
establecido como factores clave el diagnóstico preciso y el tratamiento eficaz y económico de la
enfermedad.
En la actualidad, existen diversas técnicas de diagnóstico por imagen que nos permiten eva-
luar clínicamente esta enfermedad. De entre todas ellas, la tomografía por emisión de positrones
(PET por sus siglas en inglés) destaca como la técnica de referencia para la evaluación de la
perfusión y viabilidad del miocardio, que son dos de los parámetros fisiológicos más importantes
a la hora de diagnosticar y tratar a pacientes de los que se sabe o se sospecha que pueden padecer
la enfermedad de las arterias coronarias.
No obstante, y a pesar de su demostrado valor diagnóstico, el PET no ha conseguido es-
tablecerse como la técnica más utilizada a nivel global para estudios cardiacos. Los motivos son
principalmente dos: el alto coste de las máquinas y la poca disponibilidad de los radiofármacos
necesarios para ejecutar dichos estudios (ante todo debido a la corta vida media que poseen los
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radioisótopos usados como marcadores, y a que la mayoría de estos solo pueden ser producidos
por ciclotrones).
Objetivos
En esta tesis abordamos algunas de las dificultades arriba mencionadas. Para ello exploramos
nuevas aplicaciones de un radiotrazador marcado con 68Ga, el 68Ga-DOTA. La ventaja de este
radiotrazador radica en que el 68Ga tiene una vida media adecuada (68 minutos) y puede ser
obtenido de un generador de 68Ge/68Ga de manera económica.
En este trabajo planteamos y validamos el uso de 68Ga-DOTA como un radiotrazador capaz
de medir la perfusión miocárdica (MBF por sus siglas en inglés), la viabilidad del miocardio
(mediante la cuantificación de la fracción de volumen extracelular; ECV por sus siglas en inglés)
y por último la perfusión pulmonar (PBF por sus siglas en inglés). En otro orden de cosas,
propusimos una nueva metodología que permitía realizar estudios PET en los que 68Ga-DOTA
pudiese ser inyectado simultáneamente junto con otro trazador, como el 18FDG (esta técnica
recibirá el nombre de PET multitrazador). Por último, tambien desarrollamos un detector au-
tomatizado capaz de ejecutar autónomamente el análisis por espectroscopía gamma necesario
para llevar a cabo estos estudios multi-trazador, minimizando así la necesidad de intervención
humana en la realización de dichos estudios.
Métodos
Para evaluar la capacidad de 68Ga-DOTA como radiotrazador para cuantificar MBF, ECV y PBF,
se utilizaron distintos grupos de cerdos Large White. A estos se les realizó PET/TACs utilizando
68Ga-DOTA como radiotrazador. Concretamente, para los estudios de perfusión pulmonar se
utilizaron animales sanos (n = 4), que fueron escaneados en reposo. Para los estudios de perfusión
de miocardo se utilizaron 8 cerdos sanos, que fueron escaneados en reposo y bajo condiciones
de estrés inducido farmacológicamente mediante adenosina y CGS-21680 (con el objetivo de
ejecutar pruebas de reposo/estrés, como las que se realizan clínicamente a diario en cualquier
hospital). Por último, un grupo de 5 cerdos fue sometido a una intervención quirúrgica en la que
se les indujo un infarto de miocardio. 7 días tras la intervención se les realizó un PET/TAC con
68Ga-DOTA para valorar la viabilidad y la perfusión miocárdica mediante la cuantificación de
MBF y ECV.
Los mapas de MBF, ECV y PBF fueron obtenidos como parámetros de ajuste de las imágenes
PET dinámicas tomadas en cada estudio. Dichos ajustes se realizaron utilizando el modelo
farmacocinético que 68Ga-DOTA sigue en cada tejido a estudiar. Con ello se obtuvieron mapas
de perfusión miocárdica y pulmonar tanto a nivel global como a nivel regional. Estos resultados
fueron validados utilizando como referencia los valores de perfusión obtenidos con microesferas
fluorescentes inyectadas junto con el 68Ga-DOTA.
La metodología propuesta para PET multitrazador fue evaluada y puesta a punto tanto in
vitro (utilizando distintas mezclas 68Ga/18F) como in vivo (utilizando para ello 3 cerdos Large
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White que fueron inyectados con 68Ga-DOTA y 18FDG durante la misma adquisición y a los
que posteriormente se les midió ex vivo la concentración de actividad de cada radiotrazador en
el miocardio).
El detector automático de radioactividad en sangre fue construido desde cero y caracterizado
utilizando catéteres llenados con diferentes mezclas de 68Ga y 18F. Por último, el detector se testó
en cerdos (n = 3) en condiciones experimentales similares a las que podrían darse durante su uso
clínico.
Resultados
Los valores de MBF medidos con PET y con las microesferas mostraron una fuerte correlación
(r = 0.91) (pendiente = 0.96 ± 0.10, ordenada en el origen = 0.11 ± 0.19 ml·min−1·g−1). Para
el modelo de infarto de miocardio se obtuvo que los valores de MBF medidos mediante 68Ga-
DOTA-PET en el área infartada (arteria descendente anterior izquierda) eran significativamente
menores que los obtenidos en las regiones remotas (en las arterias circunfleja izquierda y coronaria
derecha, ambas con una significancia estadística p < 0.0001). El ECV se vio aumentado en la
zona infartada (p < 0.0001).
Por otro lado, la correlación entre 68Ga-DOTA-PET y la perfusión obtenida con las microes-
feras para la perfusión pulmonar demostró ser también buena (r = 0.74, p < 0.0001).
El análisis basado en espectroscopía gamma de muestras de sangre propuesto para el PET
multitrazador fue validado satisfactioramente, con una correlación excelente de r = 0.95 (p <
0.0001) entre la concentracion de 18FDG en miocardio medida con la técnica PET multitrazador
y su valor de referencia obtenido de las medidas ex vivo.
Por último, el detector de radioactividad en sangre desarrollado fue capaz de medir satis-
factoriamente bajo condiciones próximas a las reales la concentración en sangre arterial de los
cerdos en los que fue testado.
Discusión y conclusiones
El radiotrazador para PET 68Ga-DOTA resultó ser capaz de medir de manera no invasiva la
perfusión miocárdica y la fracción de volumen extraceular en cerdos que padecían infarto de
miocardio y bajo condiciones de reposo y estrés. Este nuevo trazador podría ofrecer mayor acce-
sibilidad al PET para medir de manera cuantitativa MBF y ECV gracias a que el radioisótopo en
el que está basado, 68Ga, puede obtenerse de manera económica de un generador de 68Ge/68Ga.
A todo ello podemos añadir que 68Ga-DOTA tambien sirve como radiotrazador PET capaz de
evaluar de manera precisa la perfusión pulmonar, ofreciendo así un amplio abanico de posibili-
dades como radiotrazador para estudios de imagen PET cardiovascular.
En cuanto a la técnica de PET multitrazador, la metodología propuesta nos permitió obtener
explícitamente medidas de la concentración en sangre de cada trazador de manera independiente.
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Los resultados, además, fueron validados satisfactoriamente frente a medidas de referencia ex vivo
muy similares a las obtenidas con nuestra metodología.
En cuanto al detector de radioactividad en sangre, este fue desarrollado y caracterizado
satisfactoriamente, mostrando un desempeño similar a otros aparatos presentes en la literatura.
No obstante, nuestro detector posee como característica adicional y única la posibilidad de re-
alizar estudios PET multitrazador mediante el análisis por espectroscopía gamma de la sangre
que vaya pasando entre los dos bloques de detección que lo forman.
Todos estos resultados enumerados en este resumen podrían contribuir a potenciar el uso
del PET en la práctica clínica, bien sea por la introducción del 68Ga-DOTA como un radio-
trazador rentable pero preciso para la medida de MBF, PBF o viabilidad miocárdica, o por la
implementación de estudios PET multitrazador. El uso de estudios PET multitrazador podría
reducir los costes de la técnica al acortar los tiempos de escaneado por paciente y reducir los
errores derivados de un mal alineamiento de la posición del paciente en las distintas adquisiciones.
Además, el sistema automático de detección de radioactividad en sangre podría permitir implan-
tar estos estudios PET multitrazador sin necesidad de intervención humana, lo que evitaría la
exposición a la radiación del personal técnico.


